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ABSTRACT 




Anti-angiogenic drugs have failed to show significant extended mortality, except when 
co-administered with chemotherapy drugs in clinical trials. This should be predicted by in 
vitro models, and yet 2D in vitro models of liver cancer co-administered with these two 
types of drugs show increased cell viability, contradicting clinical trials. In vitro models 
should mimic clinical trials in order to accurately predict drug outcomes. 2D in vitro 
models fail because they lack features of the cancer environment such as presence of 
stromal cells and a vasculature.  
In order to achieve a biomimetic and vascularized in vitro model that would better 
recapitulate the cancer environment, a vascularized 3D in vitro liver cancer model is 
proposed in which: 1) heterospheroids, agglomerations of liver cancer HepG2 and 
stromal cells, are fabricated and encapsulated in collagen gel; 2) heparin crosslinked, wet-
spun chitosan microfiber/electrospun chitosan mat tube are coated with endothelial cells; 
and 3) spheroids and endothelial coated electrospun chitosan mat tube are embedded 
together on Matrigel.  
Using the hanging drop method, spheroids are formed and encapsulated in 
collagen before exposure to the anti-cancer drug doxorubicin. Cell viability, bile 
canaliculi, and cytochrome p450 activity are measured afterwards, showing greater 
maintenance of liver cell function for heterospheroids in collagen gel. 
Blood vessel constructs are developed using chitosan microfibers/tubes. Chitosan 
is modified with heparin and is confirmed by Toluidine blue staining and FTIR (Fourier 
ii
Transform Infrared Spectroscopy). Fibronectin and VEGF are then adsorbed showing 
greater cell adhesion. Microfibers/electrospun mat tubes are incubated with endothelial 
cells and embedded on Matrigel resulting in vascular sprouting. 
Triculture spheroids, heterospheroids which also contain endothelial cells, and 
cell coated chitosan electrospun mat tube are combined on Matrigel to form a 
vascularized model. Triculture spheroids on Matrigel are exposed to anti-cancer drugs, 
and vascular sprouts are measured showing expected decrease in length. Spheroids and 
cell coated tube together show anastomosis and migration, and fluorescent compounds 
injected into the model show their presence in nascent lumen. 
Overall, a vascularized model is made which exhibits similar qualities to cancer in 
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CHAPTER 1  
INTRODUCTION 
1.1 Background Information 
Liver cancer is the fifth most common cancer and the third most prevalent cause of cancer 
related mortality for men worldwide.[1] Liver cancer is a result of cirrhosis of the liver due 
to alcoholism, hepatitis, and/or aflatoxin exposure. In an effort to treat this disease and 
other cancer types, anti-angiogenic drugs have been developed. 
Judah Folkman’s landmark paper on cancer and angiogenesis, posited that for a 
solid tumor to continue growing beyond the limits of diffusion, it must induce 
angiogenesis, the process by which new blood vessels are formed from pre-existing ones. 
[2] Thus, by preventing angiogenesis, it is believed that the solid tumors will either stop 
growing or even regress.  This is known as the anti-angiogenic strategy and seems to have 
been realized as a cancer treatment with the advent of such anti-angiogenic drugs as 
bevacizumab, sunitinib, and sorafenib. However, many of these anti-angiogenic drugs have 
shown minimal/negligible results in promoting overall survival of patients. 
Besides toxicity/limited efficacy, for which bevacizumab [Avastin] was discontinued as a 
treatment for breast cancer, many of these drugs have either been ineffectual or show 
minimal success. Bevacizumab, in phase III clinical trials, only showed overall survival in 
breast cancer patients of 3 months.[3] Sorafenib, which is considered a success, only shows 
significant progression free survival and a modest increase of overall survival of 3 months 
to a year. [4-6] Sunitinib showed time to tumor progression of 5.3 months, but also a high 




The reasons for the failure of the anti-angiogenic strategy is not exactly known, 
however, many theories for the intrinsic and extrinsic/acquired resistance to anti-
angiogenic drugs exist. Intrinsic resistance, resistance to the anti-angiogenic drug before 
exposure, can be the result of metastatic potential without the need for angiogenesis, 
susceptibility to hypoxia, and redundancy of angiogenic mechanisms. Metastatic potential 
without the need for angiogenesis is exemplified by breast cancer which may be angiogenic 
independent compared to other cancers such as renal or liver cancer. [9] Susceptibility to 
hypoxia varies amongst cancer types and even a specific cancer itself as exemplified by 
the varied reactions of colon cancer cells lines to bevacizumab. [10] Redundancy of 
angiogenic mechanisms is due to the fact that angiogenesis is governed by many different 
growth factors such as PDGF, FGF, and VEGF. [11] Despite this, most anti-angiogenic 
drugs such as bevacizumab only target VEGF, thus, allowing for continued angiogenesis 
via other growth factors. Acquired resistance can occur following anti-angiogenic drug 
exposure, when hypoxia brought on by the anti-angiogenic drugs causes an upregulation 
in pro-angiogenic growth factors and causes activation of an invasive phenotype. [11-13] 
Despite spending hundreds of millions of dollars and putting decades into the 
research and development of anti-angiogenic drugs, there is little to show for the effort. 
Part of the blame for the failure can be attributed to the failure of in vitro models to 
recapitulate the environment which they are modelling during the drug development 
process and, thus, accurately predict drug outcomes. 
Drug development can be divided into pre-clinical testing and clinical testing. In 
pre-clinical testing, a drug is tested on an in vitro model and then followed by animal 




development, becomes exponentially more expensive and there is a very high attrition rate 
as it is estimated that 1 in 5,000 drug candidates is able to reach market.[14] Therefore, 
determining a drug’s failure early in the drug development cycle would prevent a great 
waste of money and time given that a single drug’s development costs $403 million (US 
2000) [15]. Money saved by determining early failure could, thus, be diverted to better 
drug candidates. To this end, an appropriate in vitro model would provide a solution to the 
problem, unfortunately, most in vitro models fail to accurately model the condition they 
are testing. 
Most in vitro models are two-dimensional monocultures and therefore fail to 
recapitulate the three dimensional nature and cellular heterogeneity of the human body. 
Animal models do recapitulate dimensionality and cellular heterogeneity of the human 
body, but may differ in their physiology/biochemistry. Numerous examples where animal 
models fail to mimic humans abound. Thalidomide was tested on rats and found to be safe, 
and, thus, was marketed to relieve morning sickness. However, thalidomide has no effect 
in rats, but is a potent teratogen in human beings, resulting in mothers giving birth to 
children with deformities, namely deformed or absent limbs. Another difficulty in using 
animals as models of disease is that certain diseases such as HIV can only infect primates, 
and rodent models of HIV are only accomplished via genetic modification and with limited 
success.[16] Therefore, an in vitro model which could incorporate human cells would 
better recapitulate human physiology/biochemistry and ultimately, better predict drug 
candidates. 
A better model is herein proposed to model the aforementioned difficulties found 




involved in in vitro testing, a new model must be constructed that incorporates various 
aspects of cancer. Specifically, an in vitro model of the hepatocellular carcinoma is 
constructed which incorporates liver cancer and a vasculature together. Endothelial cell 
coated chitosan microfibers or electrospun tubes with HepG2/fibroblast spheroids 
encapsulated in Matrigel will serve as a platform to test anti-angiogenic and chemotherapy 
drugs. 
1.2 Aims 
The goal of this study is to develop a biomimetic and vascularized liver cancer model as a 
platform for anti-cancer drug testing. In order to achieve the objective, three aims are 
proposed: 
• Aim 1: To develop biomimetic multicellular cancer spheroids for anti-cancer drug 
testing. 
 
• Aim 2: To fabricate and characterize chitosan-heparin micro/nanofiber scaffolds 
seeded with endothelial cells to act as tissue engineered blood vessel as a substrate 
for angiogenesis. 
 
• Aim 3: To construct a biomimetic and vascularized liver cancer model combining 
multicellular cancer spheroids and chitosan-heparin micro/nanofiber scaffold 
recapitulating tumor angiogenesis such that a vasculature is formed to allow 
passage of a drug into the spheroid.   
 
5 
CHAPTER 2  
SPHEROIDS 
 
Aim 1 is to develop biomimetic multicellular cancer spheroids for anti-cancer drug testing. 
We hypothesize that co-cultures of HepG2, liver carcinoma, cells and stromal fibroblasts 
fabricated via the hanging drop method into heterospheroids and embedded in ECM gel, 
results in a model which recapitulates drug resistance found in cancer in vivo. 
2.1 Background 
Spheroids are agglomerations of cells shaped like a sphere. In this study, spheroids are used 
to promote vascularization. Spheroids which grow to a radius greater than 100 m will 
become hypoxic as diffusion is only capable of delivering nutrients and gases up to ~100 
m. As a result a hypoxic/necrotic core will start to form in the center of the spheroid. Such 
an arrangement in spheroids, in which there are regions of oxia and hypoxia, are similar to 
the environment found in cancer and, thus, make spheroids an ideal model system for 
cancer drug testing.[17] Furthermore, the three-dimensional arrangement of the spheroid 
maintains cell differentiation in regards to albumin production and cytochrome p450 
activity when compared to monolayer cultures. [18, 19]  [20, 21] 
There are two types of spheroids, homospheroids and heterospheroids. 
Homospheroids are composed of only one cell type, whereas heterospheroids are 
composed of multiple cell types. The multiple cell types present in heterospheroids not 
only recapitulate in vivo conditions, in which multiple cell types are present, but aids in 




study, the liver model is composed of heterospheroids formed from two types of cells: 
parenchymal cells HepG2 and non-parenchymal cells 3T3-J2 fibroblasts. HepG2 cells are 
liver cancer derived cells and serve to model the liver cancer cells.  Fibroblasts are 
connective tissue cells responsible for the secretion and remodeling of ECM via the 
synthesis of fibrillar collagen and matrix metalloproteases. Co-cultures of hepatocytes and 
fibroblasts are shown to improve liver function such as albumin secretion, urea secretion, 
and cytochrome p450 activity.  [21-28] Cancer-associated fibroblasts aid the parenchymal 
cells by not only secreting and remodeling the ECM, but also by upregulating pro-survival 
signal transduction pathways. [29-32] These cancer fibroblasts differ from normal 
fibroblasts in that they have undergone the “angiogenic switch”. The “angiogenic switch” 
refers to a phenotypic change in the fibroblast in which the fibroblast upon exposure to the 
tumor microenvironment becomes permanently “activated” producing higher than normal 
amounts of ECM and producing a-SMA. [29, 33, 34] Furthermore, these fibroblasts are 
known to remodel the environment to promote invasion/metastasis. [35, 36] Besides, 
aiding the liver cancer, fibroblasts will also serve to stabilize the structure of growing blood 
vessels, which is important in later sections. [29, 30, 37] Thus, by including fibroblasts into 
our spheroids, the spheroids will show greater resistance to the anti-cancer drugs as 
expected in vivo. 
To culture this co-culture of HepG2 and fibroblast cell, the hanging drop method is 
used. In the hanging drop method, cells are trypsanized and the appropriate number of cells 
are pipetted onto a lid. The lid is then turned over to form the droplets, in which gravity 




Agglomerations/spheroids are harvested by turning over the dish and adding to 
liquid to cause droplets with the agglomerations/spheroids to pool together. The advantage 
of using the hanging drop method is that it doesn’t require any specialized equipment, 
however, a disadvantage to this process is that it forces the formation of spheroids as a 
result of gravity, rather than as the result of cancer stem cells and their ability to form 
spheroids by themselves. However, this study is not interested in the subject of cancers 
stem cells and simply requires spheroids for their physical shape.    
Once the spheroids are harvested, they will be encapsulated in collagen gel. ECM, 
such as collagen, not only plays an important part in promoting cell survival, but is used in 
this study as a barrier to drug diffusion. ECM is critical as a natural scaffold for cells to 
adhere to and to prevent anoikis, in which detached non-cancerous cells undergo apoptosis. 
Attachment of cells to ECM is known to promote cell viability, metabolism, and 
proliferation. Along this mode of thought, attachment of HepG2 to ECM components such 
as collagen or Matrigel, or ECM analogues such as chitosan or alginate is known to 
improve HepG2 adhesion, phenotype, and proliferation. [19, 38-41] Thus, to aid in HepG2 
functionality, collagen gel is added to the model. Collagen is triple helix peptide chains 
containing the RGD peptide sequence, responsible for binding with integrins of the cell. In 
this study, heterospheroids are not embedded on collagen gel, but rather are embedded in 
the collagen gel. In vivo, the path for a drug to reach the tumor requires the molecule to 
traverse from the blood stream and through layers of cells including the tunica intima, 
tunica media, tunica adventitia, space of Disse, and normal hepatocytes to the tumor. The 
collagen gel is, thus, used to prevent the free diffusion of the drug to the spheroid. In other 




drug exposure compared to non-embedded counterparts. [42] Furthermore, the ECM of the 
tumor environment is known to have a higher stiffness than normal tissue due the greater 
expression of lysyl oxidase causing the crosslinking of collagen and has the ability to affect 
hepatocyte expression of cytochrome p450 metabolism and proliferation. [43, 44] To 
mimic this, a higher concentration of collagen gel is used to increase stiffness. 
To form a more biomimetic liver cancer model, co-cultures of HepG2 and 3T3-J2 
fibroblasts are fabricated via the hanging drop method into heterospheroids and 
encapsulated in collagen gel, resulting in a model which recapitulates drug resistance 
found in cancer. To measure this resistance, the heterospheroids are exposed to various 
drug conditions and measured for relative cell population and bile canaliculi. Measuring 
relative cell population via Alamar blue will show the effect of the cancer drugs on cell 
viability. The Alamar blue assay is a colormetric assay in which Alamar blue/resorufin is 
metabolized to ethoxyresorufin, and as a result changes color which can be used as a 
measure of cell population. To prevent, the fibroblast cell population from being included 
in this measurement of the effect of the drug on the HepG2 cancer, the fibroblasts are 
initially treated with mitomyocin C; a compound known to arrest cell growth. Measuring 
functioning of bile canaliculi via cholyl-lysyl-fluorescein (CLF) staining will show the 
ability of various 2D and 3D HepG2 cultures to maintain a functioning bile canaliculi, even 
after exposure to a choleostatic drug. Cholyl-lysyl fluorescein (CLF) is a fluorescent 
compound that resembles the bile salt cholyl glycine and so can be absorbed into the liver 
cell and become transported by a bile transporter such as MRP2 (multi-resistant protein 2) 




visualize the bile canaliculi. Such a visual assay can, thus, be used to determine the effect 
of choleostatic drugs on liver cells, as choleostatic drugs impair the bile transporters. 
2.2 Methods 
2.2.1 Culture (HepG2/Fibroblast 3T3-J2) 
Human hepatocellular liver carcinoma cell line (HepG2; gift from Dr. Charles Ross, 
Rutgers University) cells are cultured in DMEM High Glucose, 10% FBS (Biowest, 
Miami, FL), 2% penicillin and streptomycin (P/S, Gibco, Gaithersburgh, MD) and 2mM 
L-glutamine (Gibco) at 37oC and 10% CO2. The medium is changed every 2-3 days. 
Murine stromal cells (3T3-J2 fibroblasts, purchased from Howard Green, Harvard Medical 
School, Boston, MA) are maintained in DMEM plus 10% FBS and 1% P/S. 
2.2.2 Hanging Drop Method-Homospheroids and Heterospheroids 
The hanging drop technique is used to agglomerate cells into spheroids. For homospheroid 
formation, a density of 1,000 HepG2 cancer cells per 30 L is obtained. For heterospheroid 
formation, a density of 1,000 HepG2 cells and 1,000 growth-arrested fibroblasts per 30 μL 
is obtained. Using a multi-channel pipette, 30 L of cell suspension is pipetted onto the lid 
of a 100-mm Petri dish. Lid is flipped onto bottom dish to form droplets. The dish is filled 
with sterile deionized water to prevent the droplets from evaporating. Droplets are 





Figure 2.1  Hanging Drop Method Fabrication (Homospheroid and Heterospheroid). 
Schematic of hanging drop fabrication shows steps in spheroid manufacture. A) shows 
liver cancer and stromal cells being pipetted onto a Petri dish lid. B) shows lid being 
flipped over to form hanging drops. C) shows heterospheroids being  harvested. D) shows 
heterospheroids being encapsulated in collagen gel. E) shows anti-cancer drug being 
added to heterospheroid/collagen gel system. 
2.2.3 Mitomycin C 
Fibroblasts are seeded on a tissue culture plate and grown to confluence. Confluent 
fibroblasts are growth-arrested by treatment with 12 g/ml of mitomycin C (Sigma) for 2.5 
hr. After incubation, fibroblasts are washed and trypsanized prior to hanging drop method. 
2.2.4  Collagen Hydrogel 
For spheroid culture in collagen gel, approximately 50 spheroids are mixed with 0.3 mL 
collagen solution of 9 parts of type I rat tail collagen (1.2 mg/mL, BD Bioscience) and 1 
part 10x DMEM. The mixed solution is added into 24-well and incubated for 1 hr at 37C 




HepG2 culture medium is added and incubated at 37oC and 10% CO2 for anti-cancer drug 
testing. 
2.2.5 Spheroid Diameter 
To examine the spheroid growth over time, spheroids obtained from the hanging drop 
method are transferred in a Petri dish for suspension culture. Spheroid images in suspension 
culture are captured over 5 days and analyzed by Sigma Scan Pro image software (SPSS, 
Inc, Chicago, IL) to measure the diameter. 
2.2.6 LIVE/DEAD Assay 
For the Live/Dead Assay, 1 M calcein AM and 1 M ethidium homodimer (Invitrogen) 
are added to the model and then incubated at 37C for 10 min.  Following incubation, 
culture/spheroids are visualized with fluorescent microscopy using a Nikon Eclipse TI-5 
microscope. 
2.2.7 Alamar Blue Assay 
Cell population can be measured using the Alamar Blue assay, in which the dye resazurin 
is incubated with the spheroids, aliquots are taken after 1 hr, and then measured with a 
fluorometer. The absorbance values correlate with the cell population. 
10 M resazurin (Fisher) is added to 500 L cell culture media in a 24-well plate 
and incubated at 37°C for 1 hr. The samples are collected every day and transferred to 96 
well plates for the assay. After the sample collection, the cell culture plates are washed 




intensity of the samples are measured using a fluorescent microplate reader (Gemini XPS, 
Molecular Devices) at wavelengths 530 nm for excitation and 590 nm for emission. 
Alamar blue assay is performed to create: 
1) A standard assay (based on fibroblast cell population) in which fibroblasts of 
known quantity are inoculated into a 48 well plate and Alamar blue assay performed 
the next day. 
 
2) To compare 2D monolayer (HepG2) exposed with and without anti-cancer drug.    
50,000 HepG2 cells are inoculated into a 24 well plate and Alamar blue assay is 
performed on 0, 1, 2, 3, and 4 days. Culture is exposed to 10 M doxorubicin, which 
is changed every day. 
 
3) To compare 3D homospheroids embedded in collagen gel (1.2 mg/mL) exposed 
with and without anti-cancer drug on 0, 1, 2, 3, and 4 days. 3D homospheroids are 
encapsulated as described in section 2.2.4. Culture is exposed to 10 M 
doxorubicin, which is changed every day. 
 
4) To compare 3D heterospheroids embedded in collagen gel (1.2 mg/mL) and 10x 
DMEM exposed with and without anti-cancer drug on 0, 1, 2, 3, and 4 days. 3D 
homospheroids are encapsulated as described in section 2.2.4. Culture is exposed 
to 10 M doxorubicin, which is changed every day. 
2.2.8 Cell Tracker Assay 
To examine initial cell distribution of HepG2 and fibroblasts within the heterospheroids, 
HepG2 are labeled with 1 M 5-chloromethyl fluorescein diacetate (CMFDA, green cell 
tracker dye, Invitrogen) and fibroblasts are labeled with 1 M CMTPX red cell tracker dye 
(Invitrogen) for 15 min prior to addition as droplets on lid to form hanging drops. The 









2.2.9 Cytochrome p450 Assay 
Cytochrome P-450 A1 (CYPA1) enzymatic assay is performed by measuring the 
ethoxyresorufin-O-deethylase (EROD) activity. The EROD activity assay measures drug 
metabolism by measuring the ability of the HepG2 cells to convert ethoxyresorufin to 
resorufin. After 5 days of anti-cancer drug treatment, the cultures are induced to produce 
CYPA1 by 2 μM 3-methylcholanthren (3-MC, Sigma) for 48 hours. The cells are then 
washed well with PBS, followed by 1 hr incubation with 8 μM ethoxyresorufin (Sigma) in 
phenol red free culture medium at 37C. The sample medium is collected after incubation 
and the fluorescence intensity is measured at 530 nm excitation/580 nm emission 
wavelength by the fluorescence microplate reader. Resorufin (Sigma) standards at the 
range of 1-1,000 nM are used to determine the sample concentration.  
 
2.2.10 CLF Staining 
Bile canaliculi are tubes found between hepatocytes and the excretion of bile salts through 
bile transporters into these bile canaliculi can be impaired by exposure to choleostatic 
drugs. Cholyl-lysyl-fluorescein (CLF) is a fluorescent bile acid which localizes to the bile 
canaliculi, and therefore can be used as a measure of the effect of drugs on a culture of 
hepatocytes. Cultures are exposed to 10 μM CLF for 40 min and washed twice before 
visualization. For drug conditions, culture or spheroids are exposed to 20 μM cyclosporine 





2.3.1 Spheroid Diameter 
Spheroid diameters of homospheroids and heterospheroids are measured over 5 days using 
the image analysis software. Uniform spheroids with diameters between 300-400 μm are 
obtained after 2 days of culture by the hanging drop method. After plating the spheroids in 
a Petri dish for suspension culture, the spheroid diameter initially decreases due to cellular 
reorganization. The spheroid diameter then increased continuously. The diameter increases 
by 35% for homospheroids and by 14% for heterospheroids at day 5. Homospheroids 
demonstrated higher spheroid growth rate compared to heterospheroids but there is no 
statistically significant differences over the 5 days of culture.  
 
Figure 2.2 Spheroid Diameter of Homospheroids versus Heterospheroids. Graph 
compares relative spheroid diameter growth of homospheroid and heterospheroid growth 
measured over 5 days. Homospheroids shows greater spheroid diameter growth than 
heterospheroids. Ability of fibroblasts to contract may explains why heterospheroids 







Two types of spheroids are fabricated using the hanging drop technique: homospheroids 
and heterospheroids. Homospheroids are composed of one thousand HepG2 liver 
carcinoma cells each. Heterospheroids are composed of one thousand HepG2 liver 
carcinoma cells and one thousand stromal fibroblasts each. Live/Dead cell staining is 
performed with calcein-AM and ethidium homodimer to examine the viability of the cells 
within the spheroids formed by the hanging drop method. Figure 2.3 shows phase and 
fluorescent images of HepG2 homospheroids stained with the Live/Dead cell dyes. Highly 
compact cell aggregates are formed within the spheroids. Most of the cells are stained with 
green for live cells and only a few cells express red for dead cells, indicating good cell 
viability within spheroids. 
 
Figure 2.3 LIVE/DEAD Assay of Spheroid. Live/Dead assay of spheroid shows 








2.3.3 Alamar Blue Assay (Standard Curve, 2D Monolayer) 
To examine cytotoxicity and proliferation of the spheroids for anti-cancer drug treatment, 
Alamar blue (resazurin) assay is performed by treating the cells with 10 M doxorubicin. 
Figure 2.4 A) exhibits a standard curve of HepG2 cells at various cell densities determined 
by the Alamar blue assay. There is a linear relationship between the fluorescence intensity 
and HepG2 cell number. Before testing anti-cancer drug treatment in the 3D spheroid 
hydrogel culture system, HepG2 cancer cells are tested in a 2D monolayer culture system 
as a control to investigate the effect of doxorubicin. Over the 4 days of the monolayer 
culture, treatment with 10 M doxorubicin results in 54% and 17% cell viability on days 2 
and 4, respectively as shown in Figure 2.4B). In contrast, the HepG2 cells cultured without 
doxorubicin exhibit continuous increase in cell number during the culture period, 
demonstrating 334% cell growth (2.3-fold increase) after 4 days of culture. There are 
statistically significant differences between no drug and drug conditions on cell viability 








































Figure 2.4 Graphs of Standard Curve, 2D Monolayer Cultures, and 3D Spheroid 
Cultures. Graphs pertaining to cell viability as measured by the Alamar Blue assay are 
shown. A) is a standard showing fluorescence and comparable cell population. B) 
compares 2D cell culture growth with or without 10 μM doxorubicin, showing decreased 
viability upon drug exposure. C) compares cell growth of homospheroids versus 
heterospheroids and with versus without collagen gel, showing greater resistance in 
heterospheroids compared to homospheroids in non-gel conditions, and high and no 
significant difference between homospheroids and heterospheroids in collagen gel 
conditions. Values represent averages ± SD (n=3, P<0.05, *Spheroids in collagen gel vs. 
non-gel, # homospheroids non-gel vs. heterospheroid non-gel cultures. 
Alamar blue assay 
(standard curve) 
A) 
2D monolayer culture 





2.3.4 Alamar Blue Assay (Homo/Heterospheroid w and w/o Collagen Gel)  
Alamar blue assay in the 3D spheroid cultures reveals that 3D homo- and heterospheroid 
cultures in collagen gel show significantly higher drug resistance to 2D cell cultures after 
4 days of doxorubicin drug treatment as shown in Figure 2.4C). Homospheroids in collagen 
gel culture system show more drug resistance than those not cultured in collagen gel. 
Similar results are observed in heterospheroid cultures. Among cell cultures without 
collagen gel, heterospheroid culture show significantly higher drug resistance than 
homospheroids and 2D monolayer cultures, but no significant difference in collagen gel 
cultures. Results of this study indicate that stromal fibroblasts and collagen hydrogel 
culture system provide more resistance to the anti-cancer drug.  
2.3.5 Cell Tracker Assay 
To monitor HepG2 and fibroblasts within the heterospheroids, cells are labeled with two 
different fluorescent cell tracker dyes prior to spheroid formation and observed by 
fluorescent microscopy after spheroid formation by the hanging drop method. As shown in 
Figure 2.5, two cell types form the heterospheroid that are spatially controlled by the 
hanging drop method, demonstrating homotypic and heterotypic cell-cell interactions 
between HepG2 and fibroblasts. Most of the growth-arrested stromal fibroblasts are 
observed in the center core of the spheroids, whereas HepG2 are observed both in the center 






Figure 2.5 Cell Tracker Dye of Heterospheroid. Cell tracker dye of Heterospheroid 
containing HepG2 cells (in green) and fibroblast cells (in red) shows the even distribution 
of Cell tracker green stained HepG2 and Cell tracker red stained stromal cells, as evident 
by yellow overlap. 
 
2.3.6 Alamar Blue Assay (Heterospheroid Drug Exposure) 
Cell viability and growth in the 3D heterospheroid hydrogel culture system with or without 
doxorubicin treatment for 4 days are shown in Figure 2.6. 10 M doxorubicin treatment 
results in 116% and 89% cell viability on days 2 and 4, indicating high drug resistance 
compared to 2D monolayer culture, as shown in Fig. 2.4 B. For the heterospheroid hydrogel 
culture condition without doxorubicin, the cell number increased continuously throughout 





Figure 2.6 Cell Viability of Heterospheroids in Collagen Gel Exposed to Drug. 
Heterospheroids in collagen gel are exposed to 10 μM doxorubicin and Alamar blue 
assay is used to measure cell populations on day 0 through day 4. Upon drug exposure 
heterospheroid viability drops. Values represent averages ± SD (n=3, *P<0.05). 
2.3.7 Heterospheroid Drug Exposure (Phase Imaging) 
Heterospheroid morphology cultured in collagen gel with and without 10 M doxorubicin 
treatment at day 4 are shown in Figure 2.7. The doxorubicin treatment for 4 days 
suppressed the spheroid growth and results in deterioration of spheroid structure and cell 






Figure 2.7 Phase Images of Heterospheroids in Collagen Gel Exposed to Drug. 
Heterospheroids are exposed to 10 μM doxorubicin and 10x phase images of A) non-
exposed conditions and B) exposed condition are imaged.  
2.3.8 Heterospheroid Drug Exposure (Cytochrome p450 Assay) 
Cytochrome P-450 A1 (CYPA1) enzymatic assay is performed to assess the drug 
metabolism function of HepG2 in 3D heterospheroid culture system with and without the 
doxorubicin treatment. The CYPA1 assay measures drug metabolism by measuring the 
ability of the HepG2 cells to convert ethoxyresofurin to resorufin. The assay reveals that 
heterospheroids in collagen gel show significantly higher drug metabolism function than 
those without gel, indicating more drug resistance as shown in Figure 2.8. The resorufin 
production rate of heterospheroid culture with 10 M doxorubicin treatment is 0.047  
0.013 [nM/hr] for collagen gel culture and 0.015  0.002 [nM/hr]. Similar results are 





















Figure 2.8  Graph of Cytochrome p450 Metabolism of Heterospheroids in Collagen 
Gel Exposed to Drug. Graph compares cytochrome p450 drug metabolism of 
heterospheroids with or without drug and with or without collagen gel after 5 days. Graph 
shows that heterospheroid culture in collagen gel produces a greater cytochrome p450 
metabolism compared to conditions without collagen gel. Values represent averages ± SD 
(n=3, *P<0.05, collagen gel vs. non-gel cultures). 
2.3.9 CLF Staining 
To investigate the uptake and inhibition of fluorescent probe substrate (CLF) into bile 
canaliculi, CLF staining is performed on 2D HepG2 culture, 3D homospheroids, and 3D 
heterospheroids, with or without exposure to 20M cyclosporine A (transporter inhibitor). 
Green fluorescence is present along the edge of the cells, where bile transporters are located 
between adjacent hepatocytes. As shown in Figure 2.9B), the 2D HepG2 culture shows no 
green fluorescence, indicating no bile canaliculi formation. In contrast, 3D homospheroid 
showed strong expression of CLF staining, indicating good bile canaliculi formation. 
Similar results are observed in 3D heterospheroids, forming good bile canaliculi formation 
as shown by Figure 2.10D). Exposure of 3D heterospheroids to cyclosporine shows a 
decrease of green fluorescence, which indicates the efflux of the CLF substrate into bile 
canaliculi via MRP2 transporter is blocked by the Cyclosporin A inhibitor.  
 



















Figure 2.9 CLF Staining of 2D Monolayer versus 3D Homospheroids. Bile canaliculi 
is imaged using CLF staining at 10x magnification to compare 2D and 3D cultures. A) is 
a 2D HepG2 culture and B) is the subsequent CLF stained image. C) is a 3D HepG2 
homospheroid culture and D) is the subsequent CLF stained image. 3D spheroids more 
















































Figure 2.10 CLF Staining of Heterospheroids Exposed to Cyclosporine A (Transporter 
Inhibitor). Bile canaliculi is imaged using CLF staining at 10x magnification to compare 
cyclosporine exposed and non-cyclopsorine exposed heterospheroids. Fluorescent images 
of 3D spheroids show A) phase image and subsequent B) CLF stained image after 
exposure to 20M cyclosporine for 2 hrs. Fluorescent images of 3D spheroids show C) 
phase image and subsequent D) CLF stained image without exposure to cyclosporine. 




A spheroid is an agglomeration of cells shaped like a sphere resulting in a construct which 
has three dimensions, much like cancer in the human body. Furthermore, due to its shape, 
spheroids prevent the diffusion of oxygen into the core of the spheroid resulting in hypoxia 
and necrosis similar to that of a tumor. Due to these reasons, spheroids are used in this 








Spheroids are developed using the hanging drop method, in which cells in media 
are hung as droplets which form spheroids due to gravity, and are assessed to determine if 
such a construct would be a viable system to maintain cells. A LIVE/DEAD cell assay is 
performed on a homospheroid, a spheroid composed, in this case, of only the hepatocellular 
cancer revealing living cells in green and dead cells in red. As can be seen by Figure 2.3, 
the entirety of the spheroid fluoresces green with little to any red, showing that the spheroid 
is a viable system to maintain cells.  
Spheroid diameter is measured between homospheroids and heterospheroids, and 
shows no significant difference between their diameters. Spheroid diameters are often used 
as correlative with cell proliferation and growth. The fibroblasts within the heterospheroids 
are supposed to improve cell proliferation as it known that co-culture of fibroblasts and 
HepG2 cells improve this aspect of HepG2 cells, and yet the conclusion of this experiment 
does not support this claim. A theory for the disparity may be the remodeling capabilities 
of fibroblasts. Fibroblasts are responsible for remodeling ECM and as such have contractile 
capabilities. As such it can be assumed that the fibroblasts are able to contract the spheroid, 
effectively decreasing the diameter. 
To determine the effectiveness of spheroids as a culture system to maintain cell 
viability similar to conditions in vivo after exposure to anti-cancer drugs, 3D 
homospheroids and 2D HepG2 cells are incubated with doxorubicin. When exposed to the 
drug doxorubicin, the 3D model shows increased resistance to the drug compared to 2D. 
Using the Alamar Blue assay, as shown in Figure 2.4, the relative percentages are 
calculated. The 3D model in Figure 2.4 C) shows a higher cell population than the 2D 




resistance than the 2D model, and, thus, mimics in vivo conditions showing the validity of 
the 3D model as an in vitro model. As expected, 3D spheroids are able to maintain cell 
viability because of the multiple barriers within the culture, including the gel and the layers 
of cells, preventing the diffusion of the doxorubicin. Cell-cell contacts promote pro-
viability signaling and a three-dimensional culture increases the number of cell-cell 
contacts as each cell is not only in contact with another cell on the same plane, but with 
those cells on planes above and below. The results of these cell contacts is improved 
function and viability of the cell culture, including improved albumin secretion and 
cytochrome p450 activity. [45-47] The three-dimensional culture also has the ability to 
promote cancer stem cells/tumor progenitor cells in HepG2 spheroids and spheroid forming 
cancer cells in general. [48-50] 
Another aspect of dimensionality is drug exposure. In the human body, a drug is 
physically blocked from reaching the cancer by the tortuosity of the blood vessels leading 
to the cancer, limitations of diffusion through multiple layers of cells, and the over-
accumulation of extracellular matrix. [51] The monolayer culture does not have any 
physical barrier to prevent exposure of the culture to the drug and so requires only a smaller 
dosage of a drug to render the same effect as that of the in vivo condition. To mimic the in 
vivo condition, cancer cells are often embedded in hydrogels much like our collagen gel, 
which provide an additional physical barrier. [41, 52]. By being more viable than 2D 
cultures, the 3D cultures system shows itself to be a more correct drug cancer model. 
2.4.2 Co-culture 
Two-dimensional cultures as in vitro cancer models are unreliable as they fail to mimic the 




dimensionality, but in regards to cell type.  The human body consists of more than two 
hundred cell types. In terms of drug testing of in vitro cancer models, the lack of similarity 
can drastically affect the results of such testing and lead to erroneous conclusions. 
To recreate this aspect of the tumor environment, heterospheroids are made in 
which spheroids contain one or more cell type, in this case hepatocellular cancer and 
fibroblasts. It should be noted here that ideally, the fibroblasts used would be of human 
origin and of a cancerous phenotype. However, due to the difficulty in obtaining fibroblasts 
with both characteristics, 3T3-J2 fibroblasts were used instead. 3T3-J2 fibroblasts are an 
embryonic mouse line and it is assumed due to the culturing of these fibroblasts on a stiff 
surface, i.e. the tissue culture plate, and its presence near cancer cells in the spheroid, that 
the fibroblasts transform into a cancerous phenotype. In the future, fibroblasts of a human 
origin and cancerous phenotype should be used. Cell Tracker imaging is performed on the 
cells of the heterospheroid in which hepatocellular cancer cells are labelled in green and 
fibroblast cells are labelled in red. As shown in Figure 2.5, the cells distributed randomly 
as evident by the uneven distribution of green/hepatocellular and red/fibroblasts cells as 
well as large swaths of yellow showing overlap of these two types of cells. When 
heterospheroids are grown on collagen gel and exposed to doxorubicin as shown in Figure 
2.7, blebbing can be seen around the edges of the spheroid. In the future, TUNEL assay 
should be used to determine the presence of apoptosis in these images.  
Growing spheroid diameter can be correlated to tumor volume, a measure of cancer 
growth in animal studies. To this end, the spheroid diameters of homospheroids and 
heterospheroids are compared. It should be expected that given that fibroblasts are known 




significantly larger than that of homospheroids. In reality, the opposite is true as shown in 
Figure 2.2 in which homospheroids show an average diameter larger than heterospheroids 
on days 1 through 5, although not significantly different. Although, fibroblasts are known 
to aid in proliferation, they also are known for their contractile ability, hence the fibroblasts 
may have caused compaction of the heterospheroid. Tumor volume is often used as a 
correlative of tumor growth in animal studies and so the spheroid cannot be compared to 
the animal studies in this regard. 
Another experiment to determine the effectiveness of heterospheroids, co-cultures 
of HepG2 and fibroblasts, versus homospheroids, is to compare their viability after 
exposure to doxorubicin as shown by Figure 2.4C). When exposed to the drug doxorubicin, 
the heterospheroids without collagen gel show increased resistance to the drug compared 
to homospheroids without collagen gel after 4 days exposure to doxorubicin, showing 
relative percentage of 17.5  11% compared to 79.1  1.6 %. The reason for 
heterospheroid’s resistance to the anti-cancer drugs can be explained by the inclusion of 
fibroblasts which are shown to promote resistance of cancer cells towards anti-cancer 
drugs. [20, 21, 31, 53, 54] Fibroblasts promote drug resistance in a variety of manners 
ranging from the secretion of ECM components, the release of exogenous growth factors, 
and the promotion of neoangiogenesis. [31, 55-57] However, when homospheroids and 
heterospheroids are incubated in collagen gel, the spheroids show no significant difference 
between the conditions, showing comparable viability of 108.7  15.1% and 94.0  12.9%, 
respectively. The collagen gel may be the primary reason for drug resistance as it prevents 
the diffusion of the drug to the spheroid and so mask any effects of fibroblast drug 




viability. Physically, collagen can act as a barrier to prevent the diffusion of drugs and is 
used in this study to recapitulate the physical barrier a drug encounters on its path to the 
tumor. Most notably, the collagen acts like the space of Disse, which is a layer of collagen 
which separates the endothelial cells from the hepatocytes in the liver. Biochemically, 
collagen acts as an ECM substrate by which cells can adhere and can transduce signals 
through integrins to promote cell viability. This study does not delve into the etiology for 
drug resistance caused by collagen, though in the future the etiology of drug resistance/cell 
viability could be determined by encapsulating spheroids in alginate gel. Alginate gel can 
also act as a physical barrier, however, because it has no binding sites for cells, it does not 
act biochemically to promote cell viability. Thus, if spheroids in alginate gel show 
comparable viability to spheroids in collagen following exposure to an anti-cancer drug, 
then it can be concluded that the gels act primarily as a barrier to drug diffusion, rather than 
acting on signaling transduction pathways. Also required is the exposure of collagen 
culture to a vehicle/negative control. A matter in which the collagen gel in our study proves 
itself dissimilar to the in vivo environment is the amount by which it may act as a physical 
barrier to drug diffusion. The average distance between blood vessels is between 100 and 
150 μm, and is smaller in regions of the body where there is a higher metabolic need for 
oxygen such as in the brain or the liver. As such to be biomimetic, the collagen barrier 
should be approximately between 100 and 150 μm, and yet in our study, the collagen 
barrier is at least 1 cm or several orders of magnitude higher than that of in vivo conditions. 
Thus, the drug must also travel several orders of magnitude higher than it would in vivo, 




The 3D model is able to prevent choleostatic drugs such as cyclosporine A from 
affecting the bile transporters found between hepatocytes of the cell culture. Bile canaliculi 
is a thin tube formed between hepatocytes as a conduit for the excretion of bile, but only 
when the hepatocytes are properly functioning and, thus, can be used as a measurement of 
liver function. To determine the ability of a 3D model to form these bile canaliculi, 3D 
heterospheroids and 2D culture of HepG2 are exposed to CLF. The resulting images, as 
shown in Figure 2.7, reveal that the 3D model shows a much brighter green fluorescence 
of the CLF transported into the bile canaliculi, than the 2D culture. This is evident by the 
fluorescence seen surrounding the cells in the 3D model. Thus, the 3D model is superior to 
2D cultures in improving liver functionality. The functioning of the bile canaliculi can be 
inhibited by the introduction of the choleostatic drug, cyclosporine A. Cyclosporine is a 
drug which is a competitive inhibitor of bile transporters and, thus, prevents excretion of 
bile acids such as CLF into the bile canaliculi. Cyclosporine A is exposed to a 
heterospheroid, and its fluorescence is compared to a non-exposed condition. The non-
exposed condition showed greater green fluorescence compared to its exposed counterpart. 
Similar maintenance of the bile canaliculi when exposed to choleostatic drugs is evident in 
other 3D models such as the sandwich model or in Matrigel. [58-61]  In the future, other 
such assays of liver function  such as the albumin or urea assay should be performed to 
determine the effect of  these drugs on our model.
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CHAPTER 3    
VASCULARIZED MICROFIBER/ELECTROSPUN TUBE 
 
Aim 2 is to fabricate and characterize chitosan-heparin micro/nanofiber scaffolds seeded 
with endothelial cells to act as tissue engineered blood vessel as a substrate for 
angiogenesis. We hypothesize that heparin immobilized chitosan microfibers or 
electrospun tube will support enhanced VEGF binding and endothelial cells adhesion for 
angiogenesis.  
3.1 Background   
Diffusion is capable of distributing molecules of nutrients and gases up to 100 µm. As a 
result, multicellular organisms with tissues exceeding 100 µm have a vasculature which 
greatly expands the surface area and the capability of diffusion. Without this vasculature, 
cells may undergo hypoxia and soon die. As a result, the tumor hijacks the angiogenesis 
process by releasing pro-angiogenic growth factors to promote angiogenesis and 
subsequent vascularization of the tumor. The triculture heterospheroid is a model of the 
cancer, however, to complete the model of cancer angiogenesis, a blood vessel construct 
needs to incorporated. 
 We propose two types of blood vessel constructs: chitosan microfibers and 
electrospun tubes coated with endothelial cells. In which discrete chitosan 
micro/microfibers are crosslinked with heparin for fibronectin and VEGF, and seeded with 
endothelial cells to act as tissue engineered blood vessel as a substrate for angiogenesis. 
 The vasculature is composed of a variety of cell types with their own specific 




vasculature. For this study, the endothelial lines RAEC and MVEC are used. Although, 
human umbilical vascular endothelial cells (HUVEC) would be the ideal cell line to use in 
order to recapitulate human physiology due to the cell line’s human origins, their limited 
lifespan/Hayflick limit and low rate of cell division makes the cell line difficult to coat and 
successfully grow on the chitosan constructs.  
Besides, endothelial cells, cells such as smooth muscle cells, help to maintain the 
vasculature in normal, healthy tissue; however, in cancer the vasculature grow wild and 
hoary due to a lack of these cells. [62-64] An example of such cells not included in this 
model are pericytes. Pericytes, or stellate cells in the liver, are responsible for maintaining 
and stabilizing blood vessels, as well as providing growth factors and cytokines. [65] 
However, although certainly present in the normal and cancer vasculature, pericytes are 
may not be necessary for this model of cancer. Cancer vasculature has a tortuous 
architecture containing vessels of varying diameters, abnormal vascular branching pattern, 
and irregular blood flow.[62-64] Reasons for this include differential expression of growth 
factors throughout the cancer.[62-64]. The cancerous pericyte, is loosely attached to the 
vasculature, resulting in a failure to maintain and stabilize the blood vessel. [65, 66] What 
is more, fibroblasts may be able to form vascular lumen with the endothelium and without 
pericytes, thus, abrogating the need for pericytes. [67, 68]  
To serve as a scaffold for the endothelial cells, wet spun chitosan fibers and 
electrospun chitosan tubes are used. Concerning wetspun chitosan fibers, when chitosan is 
exposed to an acid it becomes a liquid, however, becomes a solid when the chitosan/acetic 
acid solution comes in contact with a strong basic solution. This chitosan/acetic acid 




needle, wet spun fibers are formed with circular circumferences of 100-150 m, similar to 
that of the aorta. 
The manufacture of electrospun chitosan tubes follows similar lines of construction 
as wetspun chitosan fibers. Briefly, electricity is applied to a chitosan/acetic acid solution 
such that a circuit is established between a needle of a syringe, from which chitosan is 
ejected, and a metal plate. The result is the formation of fibers on the micron scale which 
will together form a mat of chitosan. This chitosan mat is rolled onto a needle to form the 
tube shape and exposed to a strong basic solution of NaOH:EtOH, before being washed 
and dried. The application of this basic solution in particular is applied, as opposed to other 
solutions such as NaOH:H2O, because such a solution has been shown to improve adhesion 
and proliferation of endothelial cells on chitosan.[69] The chitosan tube is then removed 
from the needle after drying. The disadvantage of using the chitosan tube is that the size of 
the syringe and the rolled chitosan mat, make such a construct much larger than the 
physiological diameters of blood vessels in vivo and therefore such a construct would differ 
in properties such as flow. 
In both cases, the material chitosan used in the construction of the structures is not 
conducive to cell adhesion as it lacks cell binding sites. Thus, in order to aid in cell adhesion 
of endothelial cells to the structure as well as promote cell growth and differentiation, the 
structures are first modified before inoculation of cells. To this end, fibronectin or VEGF 
is included into the wet spun fiber. Fibronectin is a glycoprotein with RGD binding 
sequences involved in cellular adhesion. VEGF is a glycoprotein growth factor involved in 
the vascularization process. The use of VEGF is prohibitive due to both its expense and its 




VEGF will be bound to the microfiber mat. Heparin will serve as the binding mediator for 
both fibronectin and VEGF, and the microfiber mat. Heparin is a natural 
glycosaminoglycan which is able to bind VEGF due to its negatively charged sulfate 
groups. Use of covalently bound heparin shows greater adsorption and prolonged release 
of the VEGF or other growth factors to the surface of a material other than the material by 
itself. [70-73] As well as serving as a binding agent, there exist a synergy between heparin 
and VEGF that aids in angiogenesis. [74, 75] 
To inoculate the RAEC cells onto the structures, the structures are simply incubated 
in high density cell containing media for up to 2 hrs while being shook every 15 min. At 
this point, the cell coated wetspun chitosan fiber does not contain a lumen. To form the 
lumen within the wetspun chitosan fiber, the chitosan needs to be dissolved out of the 
structure and so the structure is incubated with a variety of enzymes to perform the 
degradation. Following dissolution of the chitosan, the natural scaffold, i.e., collagen and 
other ECM components, will serve to preserve the vessel structure. Chitosanase or 
chitinase would be the most likely candidates as enzymes used to degrade chitosan, 
however, are cost prohibitive. Instead cellulase is used as it is far cheaper than chitosanase 
and has been shown to have similar degrading power to chitosanase by cleaving the 
chitosan structure at the same β-glycoside bond. [76] Furthermore, lysozyme is used as it 
also far cheaper than chitosanase and is known to effectively degrade chitosan. Enzymes 
like cellulase and lysozyme work at an optimal pH which both happen to be around pH 5, 
however, cells survive in an environment of 7.4. A compromise between these two 




will also aid in the dissolution of chitosan as chitosan dissolves into a liquid at a pH lower 
than 7.3. 
The manner in which the endothelial cells will coat the fiber should produce a non-
fenestrated blood vessel as endothelial cells should evenly coated the fiber. Although, 
normal liver vasculature is fenestrated, the liver tumor vasculature is not. The liver tumor 
vasculature can take on an “arterialized”, i.e., tight, or “capillarized”, i.e., non-fenestrated 
phenotype, heretofore known as sinusoidal vasculature. [77-79] In this case, the sinusoidal-
like vasculature produced by RAEC should more accurately recapitulate the vasculature 
found in this particular cancer.           
These VEGF coated, heparin cross-linked chitosan fibers provide a scaffold for 
RAEC to form into perfusable blood vessels. 
3.2 Methods 
3.2.1 Chitosan 
Two percent chitosan solution is made by stirring medium molecular weight chitosan 
(Aldrich) in dH20 with 1% acetic acid overnight. Chitosan/dH20/acetic acid is then 
centrifuged at 3000 rpm for 20 min to remove undissolved chitosan. Chitosan solution is 
decanted from the pellet. Chitosan solution is sterilized through autoclave treatment. 
3.2.2 Chitosan Film 
Chitosan solution is pipetted into 48 well plate and allowed to dry overnight. Chitosan 
solution is neutralized by the addition of 0.2M NaOH for 10 min. Four conditions tested: 




media added to each well, followed by the addition of 40,000 MVEC cells into each. 10x 
and 20x phase images taken daily followed by Actin/DAPI staining. 
 
3.2.3 Heparin Crosslinking (Chitosan Film) 
Films/fiber/tube are incubated in 5mM 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
(EDC) and 2mM n-hydroxysulfosuccinimide (NHS) (Sigma) and 1mg/mL heparin (in 
those conditions that require heparin) in HEPES buffer at 37oC overnight.  
 
Figure 3.1     Diagram of EDC/NHS Crosslinking. Diagram of crosslinking process 
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3.2.4 Fibronectin Coating 
Due to the cost prohibitive nature of VEGF, fibronectin is used for preliminary testing in 
VEGF’s place. Following crosslinking, 10 g/mL fibronectin solution in dH20 is added to 
each well and incubated at room temperature overnight.  
 
 
Figure 3.2 Diagram of Heparin Crosslinking and Fibronectin/VEGF Adsorption. 
Diagram of heparin EDC/NHS crosslinking and fibronectin/VEGF coating shows A) 
Heparin EDC/NHS Crosslinking in which amide groups of the chitosan microfiber and 
carboxyl groups of the heparin are cross-linked with EDC/NHS, and B) 
Fibronectin/VEGF Coating in which Heparin binding sequences on fibronectin and 
VEGF cause binding of the two molecules to heparin. 
 
3.2.5 Toluidine Blue Staining (Chitosan Films) 
Toluidine blue (Sigma Aldrich) is a dye which stains sulfate bearing compounds, e.g., 
heparin, dark blue, and therefore, detect the presence of such a compound. Heparin cross-
linked fibers are incubated in 3 mg/mL toluidine blue dye for 10 min at room temperature. 
Images of heparin cross-linked fibers are taken before and after 10 min staining. Images 


























3.2.6 FTIR  
To determine if crosslinking mechanism between chitosan and heparin occurred, a chitosan 
film, heparin powder, and chitosan cross-linked heparin film are examined for their 
chemical groups using Spectrum 100 FT-IR Spectrometer (Perkin Elmer). 
3.2.7 Sterilization 
Film (and subsequent fibers and tubes) are sterilized for 20 min under UV radiation before 
treatment. 
3.2.8 Actin/DAPI Staining 
Cells fixed with 4% paraformaldehyde for 10 min at room temperature. Cells are washed 
twice in PBS. 1g/mL actin phalloidin (Sigma) in PBS is incubated with the sample in the 
dark for 30 min. Cells are washed twice. 1 g/mL DAPI (MP Biomedicals) is added in 
PBS and incubated in the dark for 10 min. Cells are visualized using fluorescent 
microscopy. 
3.2.8 Alamar Blue Assay (Chitosan Film) 
Cell population can be measured using the Alamar Blue assay, in which the dye resazurin 
is incubated with the spheroids, aliquots are taken after 1 hr, and then measured with a 
fluorometer. The absorbance values correlate with the cell population. 
10 M resazurin is added to 500 L media and incubated at 37oC for 1 hr. Samples 
are collected and 100 L pipetted into 96 well plate in triplicate. Fluorescent intensity of 
resazurin was measured using a Gemini XPS fluorescent plate reader at wavelengths 530 





3.2.9 Wetspinning Fiber 
Chitosan is a gel below a pH 6 and a solid above pH 6. Exploiting this property, a scaffold 
can be designed with traits similar to the physical properties of blood vessels in vivo, 
namely having a similar diameter of 100-150 m. Chitosan dissolved in acid can be ejected 
through a syringe into a basic chemical bath, causing the chitosan to precipitate and assume 
the shape of a blood vessel.  
Two percent chitosan solution is wet spun by ejecting solution through a 30 gauge 
needle into a 1:1 NaOH:EtOH bath stirring at ~350 rpm. Fibers are formed which are 
removed from the bath, washed in EtOH, and dried overnight. 
3.2.10 Instron (Tensile Properties) 
Uniaxial tensile testing using Instron (Model 3343) is used to generate a stress-strain curve 
of dry wetspun chitosan fibers in order to determine their mechanical properties. Chitosan 
fibers, measuring 1 cm, are placed in pneumatic grips with an initial gauge length of 1 cm. 
Tensile testing is then performed with a 1N load and a crosshead extension rate of 10 
mm/min. Stress is calculated by dividing force by cross sectional area which is measured 
by fiber diameter using caliper. Young’s modulus is calculated as the slope of the linear 
elastic region of the tensile stress-strain curve.  
3.2.11 Wetspun Fiber Diameter 
Using phase microscopy, images are taken and analyzed using SigmaScan Pro5 software 
for fiber diameter. Wetspun diameters are measured when fiber are dry or wet. Wet 




3.2.12 Toluidine Blue Staining (Fiber) 
Toluidine blue is a dye which stains sulfate bearing compounds, e.g., heparin, dark blue, 
and therefore, detects the presence of such a compound. Heparin cross-linked fibers are 
incubated in 3 mg/mL toluidine blue dye for 10 min at room temperature. Images of heparin 
cross-linked fibers are taken before and after 10 min staining. Images are then analyzed 
using SigmaScan Pro5 for difference in coloration. 
3.2.13 SEM 
Samples are fixed in 2% glutaraldehyde, and after washing and drying, samples are coated 
with carbon. Scanning electron microscopy (SEM) (Leo 1530 VP) is then used to visualize 
heparin complexes.  
3.2.14 VEGF Adsorption (Fiber) 
Following incubation in heparin, the fiber and the tube are briefly washed in dH20. The 
fiber and the tube are then incubated in 10 g/mL VEGF at room temperature, overnight. 
3.2.15 Anti-Flk Staining 
To determine the ability of heparin to bind angiogenic growth factors such as VEGF, anti-
Flk staining is employed to visualize VEGF in red. A chitosan fiber is heparin crosslinked 
as previously mentioned. The crosslinked fiber is then exposed to 10 g/mL VEGF 
overnight. After washing three times with PBS, anti-Flk, PE antibody (BD Pharmingen, 
1:50) is added and incubated at room temperature for 2 hrs. After washing twice with PBS, 




3.2.16 Cell Culture (MVEC/RAEC) 
Microvascular endothelial cells (MVEC; purchased from VEC Technologies, Rensselaer, 
NY) and Rat aortic endothelial cells (RAEC; a gift Dr. Eun J. Lee’s lab) are cultured in 
high glucose DMEM, 10% fetal bovine serum (FBS), 1% penicillin/streptomycin, 2 mM 
L-glutamine, 1% Insulin-Transferin-Selenium (ITS), 10 ng/mL VEGF, and incubated in 
10% CO2 at 37
oC.  
3.2.17 Cell Coating 
To form discrete blood vessels, RAEC are coated onto fibronectin coated, heparin cross-
linked chitosan fibers/tube.  
In brief, RAEC are passaged, cells are detached with trypsin, re-suspended in 
media, and subsequently centrifuged at 700 rpm for 5 min to obtain a pellet. The cells are 
counted using a hematocytometer and approximately 2 million cells are aliquoted into a 
vial. Fibers or tubes are submerged in the cell media within the vial and are incubated for 
2 hrs and shook every 15 min. After incubation, the cell media and fibers or tube are 
relocated into a p35 Petri dish. An additional 1 mL of media is added and the fibers are 





Figure 3.3 Diagram of Cell Coating (Theory). Immobilization of heparin to chitosan 






Schematic of immobilization of bioactive 
molecules  





Figure 3.4 Diagram of Cell Coating (Fabrication). Diagram of cell coating fiber and 
coring show A) RAEC cells being trypsanized and cells suspended in media, B) 
heparin/fibronectin coated fiber being added into cell media and left to incubate for 7 
days, C) combination of enzymatic and acidic degradation used to dissolve scaffold, and 
D) the eventual formation of patent blood vessel. 
3.2.18 LIVE/DEAD Assay 
For the Live/Dead Assay, 1 M calcein AM and 1 M ethidium homodimer (Invitrogen) 
are added to the model and then incubated at 37C for 10 min.  Following incubation, 
culture/spheroids are visualized with fluorescent microscopy using a Nikon Eclipse TI-5 
microscope. 
3.2.19 Degradability 
To become a perfusable blood vessel, enzymes and acids are used to dissolve the chitosan 
fiber coated with RAEC cells. Fibers coated with cells are incubated in cellulase (12 









6). To visualize the lumen, fibers coated with cells are taken at various time points during 
incubation. 
In order to evaluate the effectiveness of this enzyme mixture, the degradation of the 
enzyme mixture is compared to chitosanase. Unless otherwise indicated, degradation is 
always performed by cellulose and lysozyme. 
 Two methods are employed to determine when the fiber has been sufficiently 
degraded. The first method is simple phase microscopy in which the fiber is observed and 
considered successfully degraded once the black line along the edge of the fiber has 
disappeared. The second method is staining the fiber with trypan blue, since trypan blue 
stains positively charged materials such chitosan, and observing the degradation of the blue 
chitosan material. 
3.2.20 Electrospinning Chitosan Mat and Tube Formation 
Electrospun mat is prepared by dissolving 8% medium molecular weight chitosan in 
trifluoroacetic acid and methylene chloride. A positive voltage of 20 kV is applied to the 
solution and delivered through a 22 gauge needle at a rate of 5 mL/hr with a syringe pump. 
The electrospun mat is collected on an aluminum plate (10 cm x 10 cm). The distance 
between the syringe and the collecting plate is 10 cm. Electrospun mats are stored in a dry 
environment to remove acetic acid. 
Square sections (1 cm x 1 cm) are rolled tightly around a 22 gauge needle to form 
electospun tubes. The electrospun tubes on 22 gauge needles are neutralized in 1M NaOH 






Figure 3.5 Schematic of Electrospun Mat Tube Fabrication. Schematic of forming 
electrospun mat into a tube is diagramed. A) shows electrospun chitosan mat being 
wound tightly around 22 gauge syringe needle, B) shows  neutralization of mat in 1M 
NaOH:EtOH solution for 10 min and subsequent washing in dH2O overnight, and C) 






Figure 3.6 Photographs of Electrospun Mat Tube. Photographs of finished chitosan 
electrospun tubes show dimensions and presence of a hollow lumen.  
 




3.2.21 LIVE and Hoechst Staining 
 
Calcein AM is used to fluoresce living cells and Hoechst dye is used to stain nuclei, in 
order to determine presence of cells on chitosan electrospun tube. 1 M calcein AM and 1 
M Hoechst dye are added to the model and then incubated at 37C for 10 min.. Following 
incubation, culture/spheroids are visualized with fluorescent microscopy using a Nikon 
Eclipse TI-5 microscope. 
 
3.2.22 Vascular Sprouting (Fiber/Tube) 
To assess the fiber/tube’s ability to allow angiogenesis to occur, the fiber/tube are 
embedded on Matrigel, and images of the vascular sprouting occurring on the fiber/tube 
are taken on days 1, 4, and 7. Length of vascular sprouts are measured using SigmaScan 
Pro5 software. Due to the possibility that fibers from the electrospun tube could unwind 
and form what appear to be vascular sprouts, a non-cell coated tube is also embedded in 
Matrigel to serve as a control and determine whether such an event occurs. 
3.3 Results 
3.3.1 Toluidine Blue Staining (Film) 
Toluidine blue staining of a chitosan (control) film and chitosan cross-linked with heparin 
film shows that chitosan control film maintains its white coloration following dyeing. In 
contrast, chitosan cross-linked with heparin film shows blue coloration following dyeing, 






    
    
Figure 3.7 Toluidine Blue Staining of Chitosan/Heparin Films. Toluidine blue staining 
images are taken. The first two images shows chitosan film (control) A) before staining 
and B) after staining. The last two images shows chitosan heparin film A) before staining 
and B) after staining. The control condition shows only pale/opaque coloration, compared 
to the Prussian blue/purple coloration in the chitosan heparin condition. 
 
3.3.2 FTIR 
FTIR graph of the chitosan film, heparin powder, and chitosan crosslinked with heparin 
film shows similarity of absorbance peaks between heparin powder and chitosan cross-
linked with heparin film at 1230 nm-1 and 1040 nm-1. These peaks represent the SO3  








Figure 3.8 FTIR Graph of Chitosan, Heparin, and Chitosan Heparin Films. FTIR graph 
of chitosan film, heparin powder, and chitosan crosslinked with heparin film, shows 
similarity between chitosan crosslinked with heparin and heparin powder at 1230 nm-1 and 
1040 nm-1, which correspond to sulfate groups known to be present in heparin. N=4. 
3.3.3 Phase Imaging  
The surface properties of a material affects cell viability. As evidenced below the varying 
tissue culture and modified chitosan surfaces results in continued adherence to the surface 
after six days for tissue culture plate and chitosan heparin fibronectin conditions; and 
sloughing off the surface after six days for chitosan and chitosan heparin conditions.  
The tissue culture plate is chemically treated to be hydrophilic and therefore ideal for cell 
adhesion. Chitosan, though known to be biocompatible, lacks surface binding proteins like 
RGD in collagen/gelatin, and therefore cells fail to adhere to chitosan unless modified 
appropriately. Chitosan heparin couples the already lackluster cell adhesion properties of 


























glycosaminoglycan with several negatively charged sulfate groups which can act by 
electrostatically repelling cells, which are negatively charged. Chitosan heparin fibronectin 
is modified with fibronectin which negates many of the poor cell adhesion properties of 
chitosan and heparin. Fibronectin is a glycoprotein which in conjunction with heparin has 
been shown to a have a synergistic effect on cell adhesion and cell viability. 
 
Figure 3.9     Phase Images of MVEC Seeded on Chitosan Modified Films. Phase imaging 
of various chitosan films shows cells at 10x magnification on day 1 on A) Tissue Culture 
Plate, B) Chitosan, C) Chitosan Heparin, and D) Chitosan Heparin Fibronectin. Chitosan 
and Chitosan Heparin films show little cell adhesion. Chitosan Heparin Fibronectin film 







3.3.4 Actin/DAPI Staining (Chitosan Film) 
Actin/DAPI Staining is performed 1 day after MVEC coating on film. Initial attachment of 
cells can be seen in Figure 3.10 A) the tissue culture plate and Figure 3.10 D) the chitosan 
heparin fibronectin conditions evident by the stained actin and nuclei. Although, cells have 
attached to both, cells in the chitosan heparin fibronectin condition shows greater cell 
spreading. 
 
Figure 3.10     Fluorescent Images of Actin/DAPI Staining of MVEC Seeded on Chitosan 
Modified Films. Fluorescent imaging of Actin/DAPI staining of various chitosan films at 
10x magnification for A) Tissue Culture Plate, B) Chitosan, C) Chitosan Heparin, and D) 










Less cell attachment can been seen in Figure. 3.10 B) the chitosan and Figure. 3.10 C) the 
chitosan heparin conditions as no stained actin or nuclei are witnessed. 
3.3.5 Alamar Blue Assay (Chitosan Film) 
Alamar Blue Assay shows the relative cell population growth for the three conditions. 
Chitosan heparin fibronectin conditions shows greater cell population growth and are 
significantly larger than chitosan and chitosan heparin conditions on day 1. These results 
support conclusions in Phase and Actin/DAPI imaging, as cells must attach to a surface in 
order to receive pro-viability signals. Tissue culture plate and chitosan heparin fibronectin 
conditions shows adhesion and chitosan and chitosan heparin conditions did not, the cells 
in the tissue culture plate and chitosan heparin fibronectin conditions were able to attach, 
spread, and grow, whereas those cells in the chitosan and chitosan heparin conditions were 
unable to attach, spread, and grow, initially. 
 
Figure 3.11    Cell Viability of MVEC Seeded on Chitosan Modified Films. Graphs show 
the Alamar Blue Assay of MVEC inoculated on varying Chitosan Films. C= chitosan, 
CH= chitosan with cross-linked heparin, and CHF= chitosan with cross-linked heparin 
and coated with fibronectin. Chitosan Heparin Fibronectin film shows significant 
difference compared to Chitosan and Chitosan Heparin on day 1. Chitosan Heparin 
Fibronectin film shows no significant difference compared to Chitosan and Chitosan 
Heparin films on day 2. Values represent averages ± SD (n=4, *P<0.05) when comparing 




























3.3.6 Instron (Tensile Properties) 
Instron testing is used to measure the mechanical properties of the wetspun chitosan fibers, 
showing a Young’s modulus of 1767.7  470.8 MPa and ultimate strength to be 51.3  
17.8 MPa. Overall, the chitosan fiber was brittle. 
 
Figure 3.12 A representative graph of Stress-Strain Curve of Wetspun Fiber. Graph 
shows the stress-strain curve of a wetspun chitosan fiber. Instron shows Young’s modulus 
of the chitosan microfiber to be 1767.7  470.8 MPa and ultimate strength to be 51.3  
17.8 MPa. (n=4) 
3.3.7 Wetspun Fiber Diameter (Dry) 
The diameter of the wetspun fibers using different gauge needles (30G vs 20G) and with 
or without the presence of flow (stir bar rotating a 350 rpm) is determined using SigmaScan 
Pro 5 to measure the distances. The average diameter for 30G with flow is 206.57  24.47  
m, for 30G without flow is 393  96.57 m, for 20G with flow is 531.93  132.1m, and 
for 20G without flow is 1123.86  274.43 m. Overall, there is a trend such that smaller 
gauge needles (30G) and flow allow for a smaller wetspun diameter size. 






Figure 3.13 Histogram of Average Diameter of Chitosan Wetspun Fiber. Histogram of 
the average diameters of the chitosan wetspun fibers shows that smaller gauge needles and 
flow conditions result in smaller diameters. N indicated in histogram, ** P < 0.05. 
3.3.8 Swelling Test 
Wetspun chitosan fibers are kept dry or made wet, and their respective diameters are 
measured for a chitosan control condition and a chitosan heparin crosslinked condition. 
The chitosan control condition shows a normalized swelling percentage of 192  24.2, 
while the chitosan heparin crosslinked condition shows a normalized swelling percentage 
of 154  24.8. Thus, the chitosan heparin crosslinked condition shows less swelling than 





Figure 3.14 Histogram of Chitosan/Chitosan Heparin Wetspun Fibers under Dry and 
Wet Conditions. Histogram of chitosan control wetspun fibers and chitosan heparin 
crosslinked wetspun fibers shows average diameters of the fibers when dry and when wet.   
3.3.9 Toluidine Blue Staining (Fiber) 
Toluidine blue staining of chitosan heparin fibers shows a change in coloration from 
naturally clear fibers to the dark blue/violet colored fibers shown in Figure 3.6. The change 
in color is an indication that the toluidine blue dye is bound to the sulfate groups of heparin, 
thus, showing the successful covalent crosslinking of heparin to the chitosan fiber. 








Figure 3.15      Toluidine Blue Staining of Chitosan/Chitosan Heparin Fibers. Toluidine 
blue staining images of fibers show A) 10x magnification of control chitosan fibers, B) 10x 
magnification of heparin cross-linked chitosan fibers, and C) 20x magnification of heparin 
cross-linked chitosan fibers. Chitosan control fibers remain opaque in color even after 









Heparin/fibronectin coated fibers are carbon coated and visualized to show complexes on 
chitosan fibers. 
    
Figure 3.16 SEM Images of Chitosan/Chitosan Heparin Fibers. SEM Images of A) 
Control (Non-coated) fiber, B) Heparin/fibronectin coated fibers, show the presence of 
complexes present in the heparin/fibronectin condition which are not present in the control 
condition.    
3.3.11 Anti-Flk Staining 
Anti-Flk (fetal liver kinase 1) staining of a control chitosan  and a chitosan heparin/VEGF 
coated fiber shows little red fluorescence for the control and strong red fluorescence for 
the heparin/fibronectin coated fiber, indicating high VEGF binding affinity to the chitosan-
heparin complex fibers. 
    
Figure 3.17 Anti-Flk Staining of Chitosan/Chitosan Heparin VEGF Fibers. Anti-Flk 
staining of A) control (non-coated) and B) heparin/VEGF coated fibers shows little red 







3.3.12 Phase Microscopy (MVEC Coated Chitosan Fibers) 
MVEC cells are placed on chitosan fibers and images are taken thereafter to determine that 
MVEC cells able to adhere to fiber and will continue to adhere to the fiber after a long 
duration, i.e., 6 days. In Figure 3.18 A), two images of MVEC coated chitosan fibers after 
1 day show that the cells were able to adhere. In Figure 3.18 B), two images of MVEC 
coated chitosan fibers (taken on the same chitosan fibers, but different locations) shows 
that cells still adhere to the fiber after 6 days.  
 
Figure 3.18 Phase Images of MVEC Coated Fibers. Phase imaging of MVEC coated 
chitosan fibers (coated with fibronectin, no heparin crosslinking) A) after 1 day and B) 








3.3.13 Live/Dead Staining (Fibers) 
Live/Dead staining of RAEC coated chitosan fibronectin fibers reveals that the fiber is able 
to maintain cell viability of the RAEC coated fibers after 3 days. Calcein AM/LIVE 
staining in Figure 3.19 B) shows considerable green fluorescence compared to ethidium 
homodimer staining in Figure 3.19 C) which shows only background red fluorescence. This 
shows that the fiber is an appropriate scaffold to maintain the RAEC cells and allow for 
their continued growth and migration across the entirety of the fiber.  
 
Figure 3.19 LIVE/DEAD Images of RAEC Coated Fibers. Live/Dead Staining Imaging 
of MVEC Coated Fiber at 10x magnification shows A) phase image, B) Live image, C) 








Images of the chitosan fiber are taken at various time points following exposure to the 
enzyme. Trypan blue stained chitosan fibers without cells are used as a preliminary test to 
determine when the fiber is sufficiently degraded before cell coated fibers are used. Cells 
coating the fibers would affect the properties of degradation due to a combination of their 
physical presence preventing the admission of acids and enzymes toward the fiber, and 
excretion of metabolites which may interact with the fiber over the course of incubation. 
Regardless, of this fact, this preliminary test is invaluable as the enzyme/acid bath is 
harmful to the cell coated on the fiber, and so by determining the absolute minimal amount 
of time necessary for fiber degradation, a greater cell viability can be had. As shown by the 
images in Figure 3.20 A) and Figure 3.20 D) , the fiber does not degrade evenly, rather 
parts of it degrade, while other parts remain insoluble as evident by the areas of blue that 
remain. Furthermore, the phenomena of swelling occurs as shown between the images in 
Figure 3.20 A) and Figure 3.20 B), in which the diameter of the fiber is shown to expand 
more than 200%. Overall, although, total degradation did not occur in an organized manner, 
the parts of the chitosan that did dissolve seem to have dissolved by around 30 min.      
           For cell coated degradation tests, the point at which the chitosan fiber is sufficiently 
degraded is herein considered to be when the straight black edge of the chitosan fiber is no 
longer seen. However, a difficulty with degradation is the swelling of the fiber resulting in 
the construct bursting at 30 min in Figure 3.21 C) and releasing cells into the surrounding 







    
    
Figure 3.20 Trypan Blue Staining of Non-Cell Coated Chitosan Fiber during 
Degradation. Trypan blue stained non-cell coated fibers in HBSS pH5.5 with lysozyme 
and cellulase are imaged at 4x magnification at A) 0min, B) 30min, C) 60min, and D) 90 








         
Figure 3.21 Phase Imaging of Cell Coated Chitosan Fiber during Degradation.     
Degradation of the chitosan fiber with the passage of time at 10x magnification show the 
effect of cellulase and lysozyme on the chitosan fiber after A)  0  min, B) 15 min, C) 30 
min, and D) 45 min, showing bursting after 30 min and cell ejection off scaffold. 
3.3.15 LIVE/Hoechst Staining (Tube) 
Live staining using Calcein AM and nucleus staining using Hoechst, reveals live cells in 
green and their nucleus in blue. As can be seen in Figure 3.22, by comparing phase with 
fluorescent images, almost all of the cells show green fluorescence and nucleus staining, 











Figure 3.22 LIVE/Hoechst Staining of Cell Coated Tube. Calcein AM and Hoechst 
staining is performed on a RAEC cell coated tube at 10x magnification. A) shows phase 
image, B) shows green/Live image, and C) shows blue/nucleus image. Fluorescent 
coloration shows presence of cells on the tube. 
3.3.16 Vascular Sprouting (Fiber/Tube) 
A non-cell coated tube is embedded in Matrigel and phase images show that after six days 
that no sprouts can be seen as shown by Figure 3.23. By contrast, both the tube and the 
fiber after being embedded in Matrigel for six days are both able to promote vascular 







   
Figure 3.23 Phase Images of Non-Cell Coated Tube. Non-cell coated tube is embedded 
on Matrigel and A) 10x or B) 20x magnification images are taken after 6 days, showing 
absolutely no sprouting. 
   
    
Figure 3.24 Phase Images of Vascular Sprouting from Cell Coated Fiber. Vascular 
sprouting is seen emerging from the RAEC cell coated fiber after 6 days at a magnification 
of 20x. A) shows sprouting angiogenesis, while B) shows maturation of the vessel by the 
addition of multiple cells. 
 
A) B) 




    
Figure 3.25 Phase Images of Vascular Sprouting from Cell Coated Tube. Vascular 
sprouting is seen emerging from the RAEC cell coated tube after 6 days at a magnification 
of A) 10x, showing sprouting angiogenesis, and B) 20x, showing vascular looping. 
3.4 Discussion 
3.4.1 Toluidine Blue Staining and FTIR  
Toluidine blue staining and FTIR are used on a heparin cross-linked film to determine that 
heparin has successfully been crosslinked to the chitosan. A film is used instead of a fiber 
as the fiber is not large enough to provide a sample large enough for study, however, it can 
be reasonably assumed that employing the same crosslinking technique on the film as the 
fiber will yield the same results.  
Toluidine blue is a dye that binds to sulfate groups, such as those found heparin, 
but not found in chitosan. In Figure 3.7 C) and D) and Figure 3.15 B) and C), an unmodified 
chitosan film and an unmodified wetspun chitosan fiber are both exposed to toluidine blue 
dye, resulting in only pale/opaque coloration. In contrast to Figure 3.7 A) and B) and Figure 





dye and shows a blue/purple coloration. Thus, the Toluidine blue assay shows that the fiber 
is successfully cross-linked with heparin. 
FTIR measures absorbance of wavelength which correlate to the chemical groups 
on the material. The most distinguishable chemical groups on heparin are sulfate, which 
has a wavelength at 1240 nm-1 and 1040 nm-1 representing SO4 assymetric and symmetric 
stretching, respectively. [80] As can be seen in Figure 3.12, there are large peaks at 
wavelengths ~1200 nm-1 and ~1000 nm-1 on the heparin cross-linked chitosan film which 
is similar in magnitude to powdered heparin, but is absent in the unmodified chitosan film, 
showing that heparin has been successfully incorporated in the chitosan heparin film.   
3.4.2 Cell Adhesion 
A preliminary test using chitosan film is employed to determine the ability of cross-linked 
heparin and adsorbed fibronectin to promote cell attachment. Chitosan is a natural, 
biodegradable, biocompatible, and anti-bacterial material, however, lacks binding sites to 
promote cell attachment. [81-83] To promote cell attachment, chitosan is chemically 
modified with RGD sequences, CAG sequences, or in this study using EDC/NHS with 
heparin. [72, 84-87] Heparin is a large negatively charged glycosaminoglycan which is 
used to attract growth factors such as fibronectin or VEGF; which in turn help promote cell 
binding. [70] 
Having confirmed heparin attachment to the film via the aforementioned Toluidine 
blue staining and FTIR, fibronectin is adsorbed to the chitosan heparin film. To determine 
the ability of the various films to promote cell adhesion, four conditions are studied: a 
control in which cells are plated on the tissue culture plate; chitosan in which cells are 




chitosan film covalently cross-linked with heparin, and chitosan heparin fibronectin in 
which cells are plated on a chitosan film covalently cross-linked with heparin and followed 
by the adsorption of fibronectin. Chitosan and chitosan heparin films show the least cell 
attachment and proliferation as shown by phase and fluorescent images in Figure. 3.9 and 
Figure 3.10. As stated before chitosan has no cell binding sites. As for chitosan heparin, 
heparin is known to be the most negatively charged glycosaminoglycan and cells tend to 
have a slight negative charge. As such the two ionically repel each other, resulting in an 
initial lack of cell attachment. However, heparin also contains binding sites for VEGF, a 
growth receptor present on the endothelial cells which allows for some binding. By 
contrast, chitosan heparin fibronectin shows the greatest cell attachment. Fibronectin is a 
glycoprotein which contains the RGD peptide sequence which promotes binding of 
integrins a5b1 on endothelial cells and, thus, has the binding capabilities to allow for 
greater cell attachment. [88] Furthermore, the combination of heparin and fibronectin has 
been shown not only to improve cell proliferation, but to improve function of pancreatic 
cells, cardiomyocytes, and sciatic nerves. [74, 89, 90]  
3.4.3 Proliferation 
Cell proliferation of cells grown on the four conditions was measured over three days. 
Tissue culture plate (TCP) and chitosan heparin fibronectin (CHF) showed the most 
proliferation, while chitosan and chitosan heparin showed the least amount of proliferation 
according to the Alamar Blue assay as shown in Figure 3.11. The cell population of 
chitosan and chitosan heparin initially decreased from day 0 to day 1, however the 
population increased from day 1 to day 2. For day 2, chitosan heparin shows a cell 




cell population it must be noted that the medium used for the endothelial cell culture 
contains the growth factor VEGF. Although, the chitosan and heparin contain no binding 
sites for cells, heparin can bind VEGF. Chitosan heparin contains heparin which binds to 
VEGF and is used in other studies to not only promote endothelial cell attachment, but 
improve cell differentiation, and capillary tube length. [75, 91] 
3.4.4 Mechanical Properties 
Mechanical properties of the tissue engineered scaffold can affect the properties of cells 
seeded on them. For endothelial cells, high stiffness can lead to dysfunction in vivo and 
expression of angiogeneic growth factors. [92-94] The measured Young’s modulus of the 
chitosan fiber is 1767.7 MPa or 1.7GPa as shown by Figure 3.11. By comparison, soft 
tissue has a Young’ modulus ~3kPa, collagenous bone has a Young’s modulus ~30kPa, 
and a tissue culture plate/glass has a Young’s modulus >1 GPa. [95] Thus, the chitosan 
fiber is highly stiff and high stiffness causes an increase in endothelial permeability and 
lowered cell-cell adhesion. [96] The lowering of cell-cell adhesion presents a problem, as 
will be reviewed in greater detail in the degradation section, as this would lower the burst 
pressure for the endothelial cell coated fiber. Though, the high stiffness may contribute to 
low burst pressure, the lowered cell-cell adhesion allows for greater angiogenesis as cells 
are freed to remodel into vascular sprouts. [97] A possibility not discussed here is that the 
chitosan fiber is tested when dry, however, because the chitosan fiber is experimented upon 
when wet, the stiffness represented by Figure 3.12 may be erroneous as a wet fiber’s 
stiffness is expected to decrease. 
 Another area of contention is the plastic deformation region. It is assumed by the 




an alternative theory for the short strain region is slip, by which the chitosan fiber in the 
grips slips out.  
3.4.5 VEGF Binding 
To determine the ability of heparin to attach VEGF onto the fiber, immunofluorescent 
staining of VEGF using Flk-1 is employed. A control/non-treated fiber and a chitosan 
heparin VEGF fiber are exposed to the immunofluorescent Flk-1 antibody as shown in Fig. 
3.17. The chitosan heparin VEGF conditions show considerable red fluorescence compared 
to the control fiber, showing that VEGF is successfully bound to the heparin coated fiber. 
Although, not used ostensibly in this model, VEGF attachment nevertheless occurs as it is 
a critical component of the endothelial cell media and so can attach to both heparin and 
fibronectin. More importantly, the application of VEGF to the chitosan fiber can be used 
in later studies, to promote angiogenesis. 
3.4.6 Cell Coating Fiber 
Imaging techniques are used to determine the ability of the wetspun fibers to adequately 
maintain cell adhesion and viability of cells coated on them. Phase imaging, as shown in 
Figure 3.18 A) and B) reveal that the cells are able to adhere onto the wetspun fiber after 
one day and remain even after six days. Furthermore, as shown by Figure 3.18 B), 
endothelial cells show a parallel and cobblestone morphology similar to that seen in vivo. 
[98] More importantly, after six days most of the fiber is covered by the cells and, thus, a 
non-fenestrated tissue engineered construct following degradation of the chitosan should 




reveals that most of the cells remaining on the fiber are green/Live and few red/Dead, 
showing that the scaffold is able to maintain cell viability.  
 The purpose of this cell coating is to create a tissue engineered blood vessel which 
will undergo angiogenesis and connect with the spheroid, much as angiogenesis occurs 
between blood vessels and solid tumor in vivo. To show that angiogenesis occurs, phase 
images are taken of the cell coated fiber and tube after embedding on Matrigel. For the cell 
coated fiber, sprouting angiogenesis can be seen in Figure 3.23 A), and vascular looping in 
which vascular sprouts combine can be seen in Figure 3.23 B). Thus, the cell coated fiber 
has successfully promoted angiogenesis. 
 Despite, the success seen in promoting sprouting angiogenesis and vascular 
looping, vascular sprouts fail to mature as they appear not to contain lumens. 
3.4.7 Degradation 
The purpose of the blood vessel is to provide a conduit for blood to flow. Thus, the most 
important feature of the tissue engineered blood vessel is the presence of a hollow lumen. 
Although, this study is more concerned with using the tissue engineered blood vessel to 
distribute anti-cancer drugs, the importance of the feature remains the same. This tissue 
engineered blood vessel differs from other such constructs in that the scaffold is only 
employed to give shape to the cells and afterwards is removed allowing for the construction 
of a discrete tissue engineered blood vessel. Cells are coated on a chitosan fiber and cells 
are allowed to grow and take the shape of a vessel. After which, the chitosan fiber is 
removed or cored. In order to core the chitosan, a combination of acidic and enzymatic 




Manual removal of the chitosan is difficult because of the minute nature of the 
tissue engineered blood vessel and because the chitosan scaffold and cells have an affinity 
for one another meaning that removal of the chitosan will also remove many of the cells. 
Chemical removal via acidic and enzymatic degradation is employed instead. The first 
technique to chemically remove chitosan is via acidic degradation. As mentioned 
previously, chitosan dissolves below a pH 7.3 and a precipates above the value, and so by 
exposing the solid chitosan fiber to an acidic environment, the fiber will dissolve into a 
liquid and out of the construct. The second technique to chemically remove the chitosan is 
via enzymatic degradation. Enzymes have the ability to degrade specific materials with an 
extremely high affinity. Chitosanase or chitinase, therefore would be the most likely 
candidate with which to degrade chitosan, however the enzyme is cost prohibitive. This 
does not necessarily preclude the use of enzymes to degrade the chitosan as other enzymes 
such as cellulase can have nearly the same effectiveness at degrading the material. [76, 99] 
In this case, it is hypothesized that the enzyme cellulase degrades chitosan as both chitosan 
and cellulase have the β 1,4-glycosidic linkage between monomers.[99]   
When fibers are exposed to pH 5.5 with 12.5mg/mL cellulase, the chitosan fiber 
begins to degrade. To assess when the chitosan fiber has completely degraded a variety of 
techniques are employed including: trypan blue staining, and phase morphology.   
The use of trypan blue to determine when the chitosan has degraded obviates from 
the usual use of the dye, as the dye is used to stain dead cells blue. In this case, trypan blue 
has an affinity for positively charged materials such as chitosan and so stains the outline of 
the chitosan fiber in blue as exhibited by Figure 3.20. When this trypan blue dyed fiber is 




3.20 A) and B). The reason for this is that the fiber can be considered a hydrogel. When in 
an acidic solution, the amide groups will obtain a positive charge resulting in electrostatic 
repulsion between the polymers of chitosan. The resulting network of polymers will allow 
the free flow of H2O into the network, forming a hydrogel and causing the structure to 
swell with H2O.  
A simpler method to determine degradation is observation under microscope. The 
generality that straight/smooth lines don’t exist in nature also applies in this study as the 
manufactured fiber, even when encased in cells, still has a straight/smooth outline. Thus, 
once the straight/smooth line is no longer seen, it can be assumed that the manufactured 
fiber has been sufficiently dissolved. 
There are limitations to using chemical degradation to core the chitosan fiber as the 
cells in the construct must remain viable and the construct must remain intact. For acidic 
degradation, a pH of 6 is used and no lower due to concerns over cell viability in a low pH 
environment. The medium used to expose the cell coated fiber is Hank’s Buffered Saline 
Solution (HBSS) due to the nutrients present to keep the cells viable and the calcium 
present to maintain the cell-cell contacts with which to keep the construct intact. When the 
cell coated fiber is exposed to the acid, it swells. This swelling has the ability to break the 
cell-cell contacts which results in the destruction of the construct. In order to reduce this, 
the construct must resist the outward force of the swelling. What is more swelling is not 
consistent as only part of the construct burst, while the remainder remained intact as shown 
by Figure 3.21 C).  
As such the fiber cannot be hollowed at present time. Since, the fiber is not 




and enzymatic treatment are not performed. Solutions to the problem could be the inclusion 
of additional cell types, most notably smooth muscle cells and fibroblasts. Circumferential 
and longitudinal strength in the blood vessel lies within the tunica media and tunica 
adventitia, the middle and outer layers of the blood vessel. Within the tunica media are 
smooth muscle cells where most of the circumferential strength lies and within the tunica 
adventitia are fibroblasts where most of the longitudinal strength lies. [100] By including 
one or both cell types onto the endothelial cell coated tube, additional strength could be 
rendered to oppose the outward swelling force. 
3.4.8 Cell Coated Tube 
As an alternative to the fiber, a cell coated tube is proposed. The tube is constructed by 
wrapping a chitosan electrospun mat around a 22 gauge syringe needle, neutralizing the 
mat with NaOH, followed by washing, and drying. After removal from the needle, the tube 
is processed in the same manner as the fiber in order to crosslink the structure and coated 
it was cells. It must be noted that unlike the fiber, the size of the tube is much larger and, 
thus, cannot recapitulate the diameter of the blood vessel in vivo. Although, this would 
alter the fluid dynamics of flow within the tissue engineered blood vessel, this project 
employs the tissue engineered blood vessel solely as a means of delivery and such an 
enlarged diameter should not present a problem.         
To ensure that such a construct could support the viability of cells presented on it, 
cells on electrospun tubes are visualized using Live/Calcein and Hoechst/nucleus staining. 
Phase imagery is unable to determine presence of cells on the electrospun tube due to the 
non-transparent nature of the chitosan electrospun mat. As such fluorescent imagery must 




by ethidium homodimer as the chitosan electrospun mat is autofluorescent for the color 
red. The results of this experiment as shown in Figure 3.22, show numerous nuclei on the 
surface of the tube in Figure 3.22 C), proving that the tube allows for cell coating, and the 
equally numerous green stained cells shows that the tube is able to maintain cell viability 
in Figure 3.22 B).  
To determine the ability of such a construct to promote angiogenesis, a cell coated 
tube is embedded on Matrigel. After a week of incubation in the Matrigel, vascular sprouts 
can be seen along the sides of the vascular construct, as shown in Figure 3.24, thus, showing 
that such a construct can support angiogenesis. The early steps of angiogenesis are evident 
as seen in Figure 3.24 A), in which tiny finger-like protrusion can be seen emerging from 
the vessel bed. Further steps in angiogenesis are seen in Figure 3.24 B), in which the ends 
of the vascular sprouts combine together to form a vascular loop. 
Although, early steps in angiogenesis can be witnessed in such a model, the 
vascular sprouts never form mature lumens. This can be remedied in the future by the 
inclusion of a second coating of fibroblast cells or the introduction of flow through the 
tube. [101-104] In order to stabilize the vascular sprouts, mural cells are required to interact 
with the endothelial cells. The most notable of these is the pericyte, as mentioned 
previously, however in vivo and in vitro it is also known that the fibroblast can also serve 
to stabilize the structure and can aid in the vascularization of the spheroid. [105, 106] 
Hence, a second cell coating of fibroblasts done in a similar manner to that of the first 
coating of endothelial cells, should be able to promote the mature vascularization of the 
cell coated tube. Another manner to promote mature vascularization is the introduction of 




unknown, the presence of flow is known to promote maturation of vessels in vitro, as well 
as in wound healing and development. 
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CHAPTER 4  
VASCULARIZED CANCER MODEL 
 
Aim 3 is to construct a biomimetic and vascularized liver cancer model, in which 
multicellular cancer spheroids and chitosan-heparin micro/nanofiber scaffolds seeded 
with endothelial cells are combined .recapitulating tumor angiogenesis such that a 
vasculature is formed to allow passage of a drug into the spheroid.  . We hypothesize that 
this model can be used to characterize the effect of drugs on vascular sprouts, anastomosis, 
migration, and transportation of drugs through cancer.   
4.1 Background 
As mentioned previously, anti-angiogenic drugs have failed alone as a cancer treatment, 
however, co-administration with chemotherapy drugs has been shown to greatly improve 
clinical outcomes. [5, 6, 107, 108] Thus, co-administration has breathed new life into anti-
angiogenic drug therapies, but at the same time has illuminated a problem with cancer 
research: in vitro versus clinical results. 
 Clinical results should be predicted during the initial phases of drug testing, 
however, aren’t and can be blamed on broad assumptions. The drug testing process, in 
brief, begins with in vitro testing, followed by animal studies, and finally followed by 
clinical trials. Clinical trials are the most expensive phase of drug testing and most telling 
as human beings, for which these drugs are being tested for, are being tested upon.  
However, because of their cost/ethical considerations, clinical trials are usually reserved 
later in the process in hopes that in vitro and/or animal testing will root out those drugs that 




that in vitro and/or animal testing will deem a drug safe/effectual that is later determined 
by clinical trials as dangerous/ineffective.  An equally valid scenario is the opposite, when 
in vitro and/or animal testing will deem a drug unsafe/ineffective, when clinical trials show 
the drug to be safe/effectual. In either case, the disparity between the results of in vitro 
and/or animal testing with that of clinical trials can be blamed on broad assumptions made 
during the course of in vitro and/or animal testing, however, as mentioned in the 
introduction, this is not the case. 
 Nowhere is the contradiction between in vitro and clinical results more noticeable 
than in Manov et al. and Abou-Alfa et al. In clinical trials performed by Abou-Alfa et al., 
co-administration of sorafenib and doxorubicin shows a mean overall survival of the 
patients of 13 months compared to 3 months when sorafenib is administered alone. [109] 
In an in vitro experiment performed by Manov et al., co-administration of sorafenib and 
doxorubicin in a Hep3B/HepG2 model, showed an increase in cell viability. [110] The 
results of this in vitro experiment run counter to clinical results, however, can be explained 
by the molecular mechanisms by which each drug causes apoptosis. Doxorubicin can cause 
apoptosis via the sustained upregulation of the MAPK/ERK pathway. [111] Sorafenib can 
cause apoptosis via the downregulation of the MAPK/ERK pathway via B-Raf blockage. 
[6, 112] Thus, the two drugs counteract each other. Sorafenib, though, has other means by 
which to cause apoptosis, namely via the anti-angiogenic strategy in which 
hypoxia/ischemia induces apoptosis. In the model system devised in Manov et al., hypoxia 
is lacking as it is a 2D monoculture and so the culture is always sufficiently oxygenated. 
Admittedly, Manov et al. noted this fault in the model and are justified in that the purpose 




mechanism.  However, if the purpose of such a model is not to determine the effect of 
molecular mechanisms and instead is used for in vitro drug testing, then this in vitro model 
would predict co-administration of doxorubicin and sorafenib to be ineffectual.  In order 
to address the problems involved in in vitro testing, a new model must be constructed that 
incorporates various aspects of cancer including vasculature and hypoxia into its design. 
Hypoxia is an important aspect that needs to be incorporated into an in vitro 
model’s design and is difficult to recreate in a 2D model, thus, requiring a 3D model. The 
effect of hypoxia on cancer has become a focus of research in recent years due to the wide 
range of effects hypoxia has on cancer. Through a series of mutations, a cell begins to grow 
uncontrollably and forms the nascent tumor. [1, 113] Initially, simple diffusion is able to 
transport nutrients and gases throughout the nascent tumor. However, when the tumor 
reaches the size of ~1 mm3, transport of nutrients and gases via simple diffusion is no 
longer possible resulting in a hypoxic/necrotic core within the tumor. [2, 114] The hypoxic 
conditions results in the modulation of various signal transduction pathways. Under the 
normal conditions of oxia, the transcription factor HIFa interacts with Von Hippel Landau 
(VHL) factor and becomes ubiquitylated for proteosomal degradation. However, during 
hypoxia HIFa is transported into the nucleus where it dimerizes with HIFb, interacts with 
hypoxia related elements (HRE), and transcribes tumor angiogenic factors. [11, 13, 115-
118] Specifically, VEGF is transcribed which causes sprouting angiogenesis to relieve 
hypoxia in the affected area. When, anti-angiogenic drugs are used to halt the angiogenesis 
process, critical nutrients and oxygen are deprived from the tumor resulting in tumor 
starvation and hypoxia which leads to tumor necrosis. [12, 119, 120] The tumor 




clinical and in vivo studies, however, is absent in Manov et al., thus explaining why a 
combination of sorafenib and doxorubicin showed growth instead of cell population 
decline. 
 However, the hypoxia following exposure to the anti-angiogenic drug leads to drug 
resistance. Hypoxia leads to the stabilization of HIF-a, which is able to dimerize with HIF-
b and forms a complex which activates gene expression. [11, 13, 115] Most notable of the 
genes expressed is MDR-1 which transcribes the drug efflux protein P-gp. Also, hypoxia 
can lead to acquired drug resistance, when the hypoxia leads to the upregulation of 
alternative pro-angiogenic signals pathways such as PI3K/Akt. [6, 108] Overall, hypoxia 
leads to drug resistance and an accurate model should mimic both the initial decrease in 
viability due to tumor starvation/hypoxia and the drug resistance due to the hypoxia 
resulting from exposure to the anti-angiogenic drugs.  
To mimic tumor angiogenesis and hypoxia, a biomimetic and vascularized liver 
cancer model is fabricated in which multicellular cancer spheroids and chitosan-heparin 
micro/nanofiber scaffolds seeded with endothelial cells are combined together on Matrigel 
.recapitulating tumor angiogenesis such that a vasculature is formed to allow passage of 
a drug into the spheroid.   
Due to the abnormal growth of cancer and the failure of angiogenesis to meet the 
oxygen/nutrient needs of the growing cancer, differential regions of oxia and hypoxia are 
created within the tumor. A spheroid is able to mimic these differential regions of oxia and 
hypoxia given its geometry; in which cells on the outer layer cells are exposed to oxygen 
and nutrients, while those cells of the interior fail to receive oxygen and nutrients. Liver 




model, the spheroid’s ability to create a region of hypoxia is taken advantage of.  The 
hypoxic/necrotic core of the spheroid causes the upregulation of a variety of tumor 
associated factors, specifically VEGF. Local blood vessels react by undergoing 
remodeling, in which the basement membrane of the vessel disintegrates, endothelial cell 
junctions dissolve, and the endothelial cells remodel to form a vascular sprout. [121, 122] 
The vascular sprout will grow along the chemotactic gradient of tumor angiogenic factors 
toward the source of hypoxia/tumor and proceed to form blood vessels in the region until 
oxia is restored.   
Ideally, such a model would be able to mimic the path an anti-angiogenic drug takes 
from the bloodstream through the tumor vasculature and into the tumor. Our model should 
accomplish this as the hypoxia derived from the spheroid’s geometry is like the solid tumor 
and will cause vascular sprouting and angiogenesis from the endothelial cells coating the 
cell coated tube which will proceed to form a vasculature with the spheroid. Angiogenesis 
should bridge the spheroid and the cell coated tube, and would be able to allow the passage 
of drugs into the spheroid. Part of this tumor vasculature is exhibited in the previous section 
in which vascular sprouts are seen emerging from the cell coated tube and would ideally 
vascularize the spheroid. However, that takes time and due to the limited lifespan of in 
vitro models it is not possible for vascular sprouts from the cell coated tube to vascularize 
the spheroid. Thus, the spheroids must be pre-vascularized and form their own vascular 
sprouts which can anastomize with the vascular sprouts and bridge the cell coated tube 
with the spheroid. To pre-vascularize the spheroids, endothelial cells are added to the cell 
media used in forming the hanging droplets to create triculture spheroids made of HepG2, 




Ostensibly, a model of cancer angiogenesis would minimally require the cancer 
cells in question and endothelial cells, however, fibroblasts aid in cell survival and to 
promote vascular sprouting. In regards to angiogenesis, fibroblasts provide soluble growth 
factors such as VEGF and interact with endothelial cells to promote vascular sprouting and 
networking. [67, 101, 123-127] Besides, producing vascular sprouts, endothelial cells, 
much like fibroblasts, can improve urea metabolism, albumin metabolism, and bile 
canaliculi/CLF staining of HepG2 cells co-cultured with it. [22, 128-132] 
To aid in the formation of vascular sprouts to form from the triculture spheroids, 
the triculture spheroids will be cultured on Matrigel. Matrigel is collagen IV and other 
extracellular matrix components derived from the Engelbreth-Holm-Swarm (EHS) mouse 
sarcoma and promotes the vascularization of endothelial cells. Hence when endothelial 
cells are cultivated in heterospheroids on Matrigel, the endothelial cells will form vascular 
sprouts that emanate from the spheroid, much like how vascular sprouts would emanate 
from the aortic ring in the aortic ring assay. Anti-angiogenic drugs affects angiogenesis, 
preventing vascular sprout growth. Thus, when our model is exposed to an anti-angiogenic 
drug, the vascular sprouts will stop growing or even regress and so the model can be used 
to assess the anti-angiogenic capability of a drug. For this study, the anti-angiogenic drug 
sorafenib is used. Sorafenib/Nexavar blocks VEGF and PDGF receptors, prevent HIFa and 
VEGFa expression, and block the Raf/MEK/ERK signal transduction pathway. [6, 133, 
134] 
Vascular regression is the remodeling and pruning of the vasculature as a result of 
drug exposure as mentioned previously, or naturally. The natural occurrence of vascular 




anastomize with each other and/or form lumens. The presence of fibroblasts and paracrine 
factors elicited by the fibroblasts is able to stabilize the vascular sprout by expressing the 
pro-stabilization factor Ang-1. [135] Given presence of fibroblasts in our model, the 
vascular sprouts should be able to remain stable and grow overall in the absence of drugs. 
Furthermore, due to the unregulated expression of VEGF and other growth factors, and 
irregular oxygen supply in cancer, it is a question whether vascular regression even occurs 
in cancer. [136] Thus, natural vascular regression should not present a problem for the 
vascular sprouting assay. 
Besides physically connecting spheroids and cell coated tube, the model must also 
prove itself perfusable, such that an anti-angiogenic drug can travel from the tube into the 
spheroid. In animal studies proving that an implanted model is perfusable requires a simple 
injection of a fluorescent dye into the bloodstream. If the implanted model has connected 
with the surrounding native vasculature and if the vasculature within the model contains a 
lumen, then upon dissection of the animal, the fluorescent dye should be revealed within 
the model’s vasculature network. An in vitro model does not have the same option as it is 
difficult, using tools available to the common laboratory, to inject fluorescent dye into such 
a system due to the diminutive size of the vasculature and a lack of a point of entry. The 
cell coated tube abrogates this problem as the cell coated tube is large enough such that a 
pipette is able to inject fluorescent compounds inside.  
As an additional experiment, the triculture spheroid on Matrigel can be used as an 
alternative to the rat/mouse aortic ring assay. Assays of the effect of an anti-angiogenic 
drug on endothelial cells usually employ the rat/mouse aortic ring assay, an in vitro assay 




the vehicle, followed by the measurement of the length or area of the vascular sprouts. 
[137] Although, the aortic ring assay is the standard model, it is not without problems. The 
aortic ring assay measures the effect of a vehicle on rodent endothelial cells, which may or 
may not be similar to human endothelial cells. Also, the aortic ring assay may lack 
consistency as the population of cell types may differ due to the variation inherent amongst 
specimens. Even the sex of the rodent may effect angiogenesis as male specimens are more 
angiogenic than female specimens. The most notable problem with the aortic ring assay, 
especially when used to measure the effect of anti-angiogenic cancer drugs is the fact that 
the aortic ring is an aortic ring without the presence of cancer cells. Cancer cells are critical 
to the process of tumor angiogenesis and have been shown in vitro to aid in the process of 
angiogenesis and vascularization in vitro due to cell-cell contact and/or release of growth 
factors. [78, 138-140]  More importantly, endothelial cells can interact with the cancer cells 
altering the metabolism of cultures reacting various drugs. [141] To remedy some of the 
problems inherent with the aortic ring assay, an alternative model is proposed by 
incorporating endothelial cells into our previous heterospheroid model of cancer. Such a 
model would be an improvement over the aortic ring model in that 1) each spheroid would 
have a consistent population of cells relevant to cancer angiogenesis, 2) wouldn’t require 
the use of animal models or surgical procedures to remove the aortic ring, and 3) include 








4.2.1 Culture (HUVEC) 
Human umbililcal vascular endothelial cells (HUVEC; ; a gift Dr. Eun J. Lee’s lab) are 
cultured in endothelial cell growth medium (EGM-2 Bulletkit Lonza) containing basic 
fibroblast growth factor (bFGF), EGF, insulin-like growth factor-1 (IGF-1), VEGF, 
hydrocortisone, ascorbic acid, heparin, gentamicin, and amphotericin-B. All cultures are 
incubated in 10% CO2, 37
oC incubator. 
4.2.2 Hanging Drop Method-Triculture Spheroid 
Triculture spheroids are fabricated using the hanging drop method, as described previously 
in Section 2.2.2. To obtain triculture spheroids, 1,000 HepG2, 1,000 growth arrested 3T3-
J2 fibroblast cells, and 1,000 endothelial cell (RAEC or HUVEC) in 30 L droplets, 
containing RAEC or HUVEC media depending on endothelial cells used, are plated on a 
100 mm Petri dish and inverted. Spheroids are harvested after 7 days. 
 
4.2.3 Vascular Sprouting (Length) 
When cultured in spheroids and grown on Matrigel, endothelial cells have the potential to 
form vascular sprouts. The length of these sprouts can be used to assay the effect of various 
drugs on the vascularization of a tumor. The spheroids are incubated on the surface of 
Matrigel and sprouting is allowed to occur over the course of 7 days. The spheroids are 
then exposed to various concentrations of a drug (sorafenib: 0M, 5M, and 10M). 





4.2.3 Vascular Sprouting (Immunohistochemistry) 
To ensure that the vascular sprouts are indeed the product of endothelial cell induced 
angiogenesis and not one of the other cell types masquerading as vascular sprouts, such 
vascular sprouts are stained for CD31, an antibody pertinent to endothelial cells. Triculture 
spheroids are harvested after 7 days. Collagen gel (1.2 mg/mL) and 10x DMEM is allowed 
to gel at 37oC for 30 min and spheroids are embedded on top of the gel. Sprouts are allowed 
to grow on the collagen gel surface for another 7 days. The culture is then fixed with 4% 
paraformaldehyde for 10 min before being stained with FITC mouse anti-human CD31 
(BD Pharmingen) (1:50) in PBS overnight at 4oC.  
Figure 4.1 Design of Vascularized Model. Design of vascularized model is featured 
showing the fabrication of the model, starting with A) the embedding of both spheroids 
and vascular tube on Matrigel, B) spheroid and vascular tube forming vascular sprouts, 







Vascular sprouting is shown to independently occur in the triculture spheroids and the cell 
coated tube. When placed together in the same culture, it is possible for these vascular 
sprouts emanating from the triculture spheroid and cell coated tube to interact with each 
other in what is known as anastomosis. To record this event, triculture spheroids and cell 
coated tube are embedded together on Matrigel and monitored over the course of time for 
interactions between the vascular sprouts. 
4.2.6 Migration 
Migration of spheroids toward the fiber/tube is evident in some circumstances. By taking 
images at various time intervals, the migration can be monitored. 
4.2.7 Fluorescent Dextran/Doxorubicin Injection 
To prove that vascular sprouts of the spheroid and the cell coated tube have anastomized 
and formed a lumen, FITC dextran (70kDa) or doxorubicin is injected into the cell coated 
tube. If a lumen is formed between the cell coated tube and spheroid, and no physical 
leakage has occurred, then fluorescent dextran/doxorubicin should only be viewed in the 
regions of the cell tube, the vasculature between the tube and the spheroid, and within the 
spheroid itself. Note, doxorubicin, as well as being a chemotherapy drug, is slightly 
fluorescent for the color red and, thus, can be used to show the distribution of the drug 





4.3.1 Vascular Sprout (Drug Testing) 
Images of vascular sprouts emanating from the spheroid were taken and length of sprouts 
are measured by SigmaScan Pro5. For all conditions the vascular sprouts in the 
0uM/control condition showed continued sprout length growth. In contrast, vascular 
sprouts in drug exposed (5M and 10M conditions) show a decrease sprout length 
growth. For the 10M condition, there cease to be any vascular sprouts present by day 4. 
There is a significant difference (n=10, **p<0.005) between the 0M/control and the drug 
exposed conditions for each of the following days. 
 
Figure 4.2 Triculture Spheroid (HUVEC) Vascular Sprout Length Exposed to Anti-
Angiogenic Drug Sorafenib. Lengths of the vascular sprouts in HUVEC triculture 
spheroid when exposed to sorafenib shows for 0M/control condition increased growth, 
whereas 5M and 10M conditions shows decreased growth. Sprout length is normalized 
to day 0 average before drug treatment. Values represent averages ± SD (n=10, *P<0.05, 
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Figure 4.3 Phase Images of Triculture (HUVEC) Spheroids and Vascular Sprouts 
Exposed to Sorafenib. Images of vascular sprouts from HUVEC triculture spheroids 
show vascular sprouts before and after exposure to drugs on day 1 an day 4. A) shows the 
0M/control, and B) shows the control after 4 days revealing increased growth. C) shows 
the before and D) shows the after image of HUVEC triculture spheroids exposed to 5M 
sorafenib. E) shows the before and F) shows the after image of HUVEC triculture 
spheroids exposed to 10M sorafenib. Greater concentration of sorafenib shows greater 
decrease of sprout length. 












Figure 4.4 Triculture Spheroid (RAEC) Vascular Sprout Length Exposed to 
Cytotoxic Drug Doxorubicin. Length of the vascular sprouts in RAEC triculture spheroid 
when exposed to sorafenib shows for 0M/control condition increased growth whereas 
5M and 10M conditions shows decreased growth. Sprout length is normalized to day 0 
average before drug treatment. Values represent averages ± SD (n=10, *P<0.05, ** 
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Figure 4.5 Triculture Spheroid (RAEC) Vascular Sprout Length Exposed to Anti-
Angiogenic Drug Sorafenib. Length of the vascular sprouts in RAEC triculture spheroid 
when exposed to doxorubicin shows for 0M/control condition increased growth whereas 
5M and 10M conditions shows decreased growth. Sprout length is normalized to day 0 
average before drug treatment. Values represent averages ± SD (n=10,  *P<0.05, ** 
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Figure 4.6 Phase Images of Triculture (RAEC) Spheroids and Vascular Sprouts 
Exposed to Sorafenib. Images of vascular sprouts from RAEC triculture spheroids show 
vascular sprouts before and after exposure to drugs on day 1 and day 4. A) shows the 
control, and B) shows the control after 4 days revealing increased growth. C) shows the 
before and D) shows the after image of RAEC triculture spheroids exposed to 5M 
sorafenib. E) shows the before and F) shows the after image of RAEC triculture 
spheroids exposed to 10M sorafenib. Greater concentration of sorafenib shows greater 
decrease of sprout length. 












Figure 4.7 Phase Images of Triculture (HUVEC) Spheroids and Vascular Sprouts 
Exposed to Doxorubicin. Images of vascular sprouts from RAEC triculture spheroids 
show vascular sprouts before and after exposure to drugs on day 1 and day 4. A) shows 
the before and B) shows the after image of RAEC triculture spheroids exposed to 10M 
sorafenib. C) shows the before and D) shows the after image of RAEC triculture 
spheroids exposed to 5M doxorubicin. E) shows the before and F) shows the after image 
of RAEC triculture spheroids exposed to 10M doxorubicin. Greater concentration of 
doxorubicin shows greater decrease of sprout length. 










4.3.2 Vascular Sprout (Immunohistochemistry) 
 
CD31 staining of the triculture spheroids containing HUVEC cultured on Matrigel 
fluoresces for endothelial cells. On what is presumed to be the vascular sprouts, a majority 
of the cells fluoresce and therefore can be assumed to be endothelial cells. Non-green 
fluorescing cells are present alongside the endothelial cells on the vascular sprouts as 
evident by DAPI stained images. 
    
 
Figure 4.8 CD31 and DAPI Images of Triculture (HUVEC) Spheroids and Vascular 
Sprouts. Vascular sprouts radiating from HUVEC triculture spheroids on collagen gel are 
visualized at 20x magnification. A) shows phase image, B) shows CD31 stained image, 







4.3.3 Vascular Sprout (Live/Dead) 
 
Images of triculture spheroids show Live/Dead imaging after the addition of 10M 
doxorubicin or 10M sorafenib. Following exposure to either drug, spheroids show 





Figure 4.9 LIVE/DEAD Assay of Triculture (RAEC) Spheroids following Exposure 
to Doxorubicin. RAEC triculture spheroids are exposed to anti-cancer drugs and images 
are taken at 10x magnification. 10 M doxorubicin exposed conditions are shown in the 
first four images. A) shows the phase image, B) shows the live image, C) shows the dead 
image, and D) shows live/dead image. Considerable red fluorescence compared to green 








Figure 4.10 LIVE/DEAD Assay of Triculture (RAEC) Spheroids following Exposure 
to Sorafenib. RAEC triculture spheroids are exposed to anti-cancer drugs and images are 
taken at 10x magnification. 10M sorafenib exposed conditions are shown in the last four 
images. A) shows the phase image, B) shows the live image, C) shows the dead image, 
and D) shows the live/dead image. Considerable red fluorescence compared to green 
fluorescence shows that sorafenib has caused apoptosis. 
 
4.3.4 Anastomosis 
Anastomosis is seen occurring between vascular sprouts of the triculture spheroids and the 
vascular sprouts of the cell coated fiber/tube. Over the course of time, vascular sprouts can 
be seen independently manifesting from the triculture spheroid and cell coated fiber/tube, 
until the multiple sprouts are seen conjoining with one another. Conjoined vascular sprouts 








Figure 4.11 Anastomosis Between Cell Coated Fiber and Triculture Spheroid. 
Anastomosis between spheroid and cell coated fiber can be seen at 10x magnification after 
day A) 1, B) 2, C) 3, D) 5, and E) 7 embedding on Matrigel. Vascular sprouts deriving 









       
Figure 4.12 Anastomosis Between Cell Coated Tube and Triculture Spheroid. 
Anastomosis between spheroid and cell coated tube can be seen at A) 10x and B) 20x 
magnification after day 6.  
4.3.5 Migration 
10x phase images of single spheroid and fiber is monitored over the course of several days 
and shown in Figure. 4.13. As can be seen the spheroid is able to migrate closer to the fiber 
moving approximately 100 M distance. 10x phase images of a single spheroid and tube 
is monitored over the course of several days and shown in Figure. 4.14. As can be seen, 
the spheroid is able to migrate onto the tube after 14 days, after which the spheroid loses 











      
    
Figure 4.13 Migration of Triculture Spheroid to Cell Coated Fiber. Migration of 
HUVEC triculture spheroid toward cell coated fiber can be seen on A) 1 day and B) 3 












       
      
Figure 4.14 Migration of Triculture Spheroid to Cell Coated Tube. Migration of 
HUVEC triculture spheroid toward cell coated tube can be seen on A) 1 day, B) 3 days, 
C) 7 days, and D) 14 days after embedding on Matrigel, showing the spheroid merging 
with the tube. 
4.3.6 Fluorescent Dextran Injection 
10x images of an area including spheroid and tube shows the distribution of fluorescent 
dextran within the region. Images are that of the region 10 min after injection of the FITC 
dextran into the cavity of the tube. Failure of green fluorescence to appear solely in the 
lumen of the cell coated tube, spheroid, and vasculature shows some non-specific diffusion, 
which is expected. Some fluorescence can be seen with the vascular sprouts showing the 







   
 
Figure 4.15 Images of Vascularized Cancer Model Following Injection of FITC 
Dextran. Injection of FITC dextran can be seen at 10x magnification. A) shows phase 
image, B) shows green fluorescent image before injection of FITC dextran, and C) shows 
green fluorescent image 10 min after injection of FITC dextran. Green fluorescence can 
be seen in region of vascular sprouts. 
4.3.7 Doxorubicin Injection 
10x images of an area including spheroid and tube shows distribution of doxorubicin within 
the region. Images are that of the region 10 min after injection of doxorubicin into the 
cavity of the tube. Like fluorescent dextran, doxorubicin, evident by red fluorescence, can 
be seen throughout the model. Red fluorescence can be seen within the spheroid, however, 






     
 
Figure 4.16 Images of Vascularized Cancer Model Following Injection of 
Doxorubicin. Injection of doxorubicin can be seen at 10x magnification. A) shows phase 
image, B) shows red fluorescent image before injection of doxorubicin, and C) shows red 











4.4.1 Model Overview 
When the cell coated electrospun tube is embedded on Matrigel with triculture spheroids, 
three scenarios occur between the tissue engineered blood vessel and the spheroids. The 
first scenario is that the tissue engineered blood vessel and spheroids do not interact. The 
second scenario is anastomosis in which sprouting angiogenesis occurs between the 
spheroid and tissue engineered blood vessel, resulting in the interaction between the 
vascular tips. The third scenario is migration in which the spheroids migrate toward the 
tissue engineered blood vessel. All three scenarios occur with varying degrees within the 
model and mimic cancer within the human body.  
4.4.2 Vascular Sprout Assay 
Triculture spheroids formed from HepG2, fibroblast, and endothelial cells are embedded 
on Matrigel and are allowed to sprout before exposure to anti-cancer drugs. Such a model 
can be used as an alternative to the rat aortic ring assay and to test this, the lengths of the 
vascular sprouts are measured at different time points and with different concentrations of 
drugs. Two types of triculture spheroids are tested, those which contain the endothelial cell 
type RAEC and those that contained the endothelial cell type HUVEC. RAEC are used in 
this circumstance to help compare the triculture spheroid with the rat aortic ring assay. 
HUVEC are used in this circumstance to help connect the vasculature of the spheroid with 
that of the cell coated tube. In the future, triculture spheroids should contain all human cells 
in order to not only connect the vasculature of the spheroid with the cell coated tube, but 




In the rat aortic ring assay, a rat aorta is exposed to a vehicle and the length or area 
of the vascular sprouting is measured. In order to validate our model, vascular sprouting is 
also measured after exposure to a vehicle. In this case, our model is the triculture spheroid 
on Matrigel, and our vehicle are the drugs sorafenib and doxorubicin. As shown by Figure. 
4.8, sprouts are seen emerging from the spheroid and stain for CD31 confirming the sprouts 
as endothelial in origin. However, no negative control was performed to determine whether 
these sprouts autofluoresce for color green as a sign of CD31 expression.  In our model it 
is assumed that the vascular sprouts are the product of endothelial remodeling to form stalk 
and tip cells, rather than fibroblasts expanding. In order to determine whether these sprouts 
are endothelial or fibroblast cells, a negative control should have been performed in which 
heterospheroids are incubated on Matrigel to determine if similar sprouting can be seen. 
Given that the fibroblasts have been treated with mitomycin C to arrest growth and that 
vascular sprouts can be seen stained for CD31 as evident by Figure 4.8, it can be assumed 
that vascular sprouts are the product of endothelial cell remodeling.  In the future, to further 
verify the identity of these sprouts, GFP-HUVEC can be used and if green fluorescence is 
witnessed in the region of the sprouts, prove the presence of endothelial cells.  
  When RAEC triculture spheroids are exposed to doxorubicin and sorafenib, the 
vascular sprouts in the vehicle conditions decrease, while the control condition continues 
to increase. Comparing the drug efficiency based on vascular sprouts shows that 
doxorubicin showed a greater decrease in vascular sprouting compared to sorafenib. This 
is contrary to what is expected as sorafenib is typified as an anti-angiogenic drug and, thus, 
specifically acts on the vasculature, whereas doxorubicin is typified as a cytotoxic drug. 




of orthotopic and subcutaneous human xenografts. [142] However, sorafenib acts mainly 
on the vasculature by affecting blocking VEGF and PDGF receptors, and affects 
angiogenesis, the formation of new vessels from pre-existing vessels. Sorafenib is not a 
vascular disrupting drug and therefore does not destroy the pre-existing vasculature. 
Doxorubicin by contrast is a cytotoxic drug and would destroy the pre-existing vasculature, 
as well as other cells. As to why doxorubicin seems to be effective in this in vitro model, 
but seems to have no effect in the animal model, can be explained in terms of tumor drug 
delivery. As mentioned previously the tumor vasculature is tortuous and as such it is 
difficult to effectively deliver drugs to the tumor and for that matter the vasculature itself. 
Our model does not have any barrier to prevent the doxorubicin from affecting the vascular 
sprouts, and as such the effective concentration of doxorubicin is much higher. Similarly 
the rat aortic ring assay does not have any such barrier either and so our model is therefore 
no better or worse in that regard. A simple solution to this dissimilarity would be to add a 
second layer of gel to serve as a barrier and, thus, lower the effective concentration of 
doxorubicin.  
4.4.3 Anastomosis 
Anastomosis is the ideal condition to meet the requirement of Aim 3 as we seek to join the 
potential vasculature within the spheroids with the cell coated fiber/tube carrying the drug 
in question. HUVEC spheroids are incubated on Matrigel with either a cell coated fiber or 
tube, and show the hallmarks of anastomosis. In Figure 4.11 and Figure 4.12, both the 
spheroids and the fiber/tube are able to form vascular sprouts, though not in any specific 
direction as evident by the “sun” like formation of sprouts around the spheroids. 




meet each other as evident in Figure 4.11 C). Upon closer inspection at 20x magnification 
on day 6 as shown by Figure 4.12 B), the vascular sprouts from two different sources will 
interact with one another, resulting in the anastomosis of the spheroid to the cell coated 
fiber/tube. However, due to either a lack of pericytes and/or flow, no lumen is witnessed 
to form inside this vasculature. In the future, these properties need to be included. 
 A manner in which this model may differ from in vivo conditions is the origin of 
the vasculature within the liver cancer. In this model, the liver cancer is modeled by the 
triculture HUVEC spheroids and the origin of the vasculature within this model of the liver 
cancer is HUVEC cells that originate from the cell media of the hanging drop. This 
arrangement does not recapitulate the most common origin narrative of the tumor 
vasculature. Briefly, tumors grow to a size such that oxygen is no longer able to diffuse 
properly, resulting in hypoxia and the upregulation of pro-angiogenic factors which causes 
vascular sprouting from a local blood vessel to restore oxia. Hence, the vasculature’s origin 
is from outside the liver cancer and this seems to have been proven by Ghanekar et al. in 
which a male human cancer xenograft is implanted into a female rat. [143] The vasculature 
from the xenograft positively stains for rat CD31 and not only that, fluoresces for female 
chromosomes, showing the origin of the vasculature is from the rat, or outside the cancer. 
The local blood vessel in our model is the cell coated tube which should therefore provide 
the vasculature for the spheroid, however, due to the limited lifespan of an in vitro model 
it may not be possible for this to occur. The process of cancer vascularization takes years 
in human beings and weeks in the rat. Therefore, in order to speed up the process, HUVEC 




Although, the local blood vessel narrative is the most widely held narrative 
regarding vascular origins, there may be alternative narratives involving cancer stem cells 
and bone marrow endothelial progenitor cells. In the cancer stem cells/tumor progenitor 
cell narrative, cancer stem cells/tumor progenitor cells, stem cells present within the tumor 
can differentiate into endothelial cells. [144, 145] Similarly, in the bone marrow endothelial 
progenitor cells narrative, bone marrow derived endothelial progenitor cells travel through 
the blood stream and can colonize in the tumor where they differentiate into the endothelial 
cells. [146, 147] Based on these alternative narratives, it may be possible to justify our 
model. 
4.4.4 Migration 
Migration is not an ideal condition to meet the requirement of Aim 3 as a vasculature is not 
formed between the spheroid and fiber/tube as would be formed between the solid tumor 
and the blood vessel in vivo. HUVEC spheroids are incubated on Matrigel with either a 
cell coated fiber or tube, and show the hallmarks of migration. In Figure 4.13 and Figure 
4.14, the spheroids and the cell coated tube do not form as many vascular sprouts as the 
anastomosis condition, rather the spheroids migrate toward the cell coated fiber or tube 
over the course of several days. Migration can be explained by the presence of fibroblasts 
within the spheroids and endothelial cell coated on the tube. Fibroblasts migrate toward 
sources of VEGF and endothelial cells provide a source of VEGF. Thus, the fibroblasts 
surrounding the spheroid may cause the entirety of the spheroid to migrate toward the 
endothelial cells on the cell coated tube. Similar phenomena are witnessed in transwell 




 Altering the stiffness of the gel in which spheroids are embedded may prevent 
migration. Addition of collagen gel or other ECM analogue would increase stiffness and 
increase of hydrogel stiffness is known to prevent migration in other spheroid cultures. 
[149] However, a difficulty in manipulating stiffness of Matrigel, is that the concentration 
of protein within the Matrigel is unknown and differs amongst manufacturers and batches. 
4.4.5 Fluorescent Injection 
Fluoresecent FITC-dextran and doxorubicin are injected into a model containing HUVEC 
triculture spheroids and RAEC cell coated tubes incubated on Matrigel for 7 days, and 
serve as proxies of anti-angiogenic drugs entering into the model. The results show the 
capricious nature of the model. In the FITC-dextran images in Figure 4.15 C), green 
fluorescence can be seen to enter the vascular sprouts, proving the existence of a nascent 
lumen. However, in the doxorubicin images in Figure 4.16 C), none of the vascular sprouts 
have red fluorescence within. Similarly, in the doxorubicin images, red fluorescence can 
be seen in the area encompassing the spheroid, but in FITC dextran images, green 
fluorescence cannot be seen in the area encompassing the spheroid. Neither FITC dextran, 
nor doxorubicin are specific dyeing agents and so there is no more reason why one should 
be seen in a particular site versus the other. The images testify to the capricious nature of 
the model, in that sometimes vascular sprouts will form a lumen allowing FITC-dextran 
inside, while sometimes a spheroid will have vascularized allowing doxorubicin inside. 
Nevertheless, that these fluorescent compounds are able to enter into the vascular sprouts 
and spheroid show some success for the model in that a drug could enter through the 
vascular sprouts and that a drug could enter into the spheroid, though separately. Ideally, 




vascular sprout and then into the spheroid. Overall, the results of this experiment, confirm 
our hypothesis as the fluorescent compound, acting as the anti-cancer drug, is successfully 
transported from the cell coated tube, acting as the blood vessel, into the spheroid, acting 









The purpose of this study is to develop an in vitro model of liver cancer that recapitulates 
aspects of cancer in vivo as a platform to anti-cancer drugs. To accomplish this goal, the 
study is divided into three different aims.  
The first aim is to develop spheroids as an anti-cancer drug platform.  To this end 
homospheroids containing HepG2 cells are developed using the hanging drop method. 
Such a culture is able to maintain cell viability of the HepG2 cells. When homospheroids 
are exposed to the anti-cancer drug doxorubicin, the culture shows a greater resistance to 
the drug than a 2D monolayer, similar to resistance expected in vivo. When spheroids are 
cultured with HepG2 and fibroblast cells together as heterospheroids, they show a greater 
resistance to doxorubicin than homospheroids without collagen gel. When both types of 
spheroids are cultured in collagen gel, they both show high viability following drug 
exposure, but no significant difference. The difference between homospheroids and 
heterospheroids with or without collagen gel shows that the collagen gel may mask any of 
the effect of the fibroblast toward drug resistance. Similarly, cytochrome p450 activity is 
preserved in collagen gel after exposure to the anti-cancer drug as compared in the non-gel 
condition. A question not answered in this study is whether the collagen gel as a physical 
barrier or as a substrate is responsible for drug resistance/increased viability.  
The second aim of our study is developing chitosan based microfiber scaffolds as a 
tissue engineered blood vessel to promote angiogenesis. The material chitosan is not 





end, chitosan is crosslinked with EDC/NHS to heparin and adsorbed with fibronectin. To 
test this, chitosan film is first modified. To confirm heparin’s binding to chitosan, toluidine 
blue staining and FTIR are used to analyze heparin crosslinked chitosan films, and shows 
its presence. A cell adhesion study using phase imagery, Actin/DAPI staining, and Alamar 
blue assay shows that chitosan film crosslinked with EDC/NHS to heparin and adsorbed 
with fibronectin is able to promote cell adhesion and proliferation. Similar modification to 
a chitosan wetspun fiber shows similar results in that cells are able to adhere to the construct 
as shown by phase imagery and Actin/DAPI staining. A chitosan wetspun fiber crosslinked 
with EDC/NHS to heparin and adsorbed with VEGF is immunostained with anti-Flk-1 and 
shows that the fiber is able to bind VEGF. VEGF is a critical growth factor in angiogenesis, 
but is expensive, and so fibronectin is used instead for the present study. For future studies, 
the use of VEGF would be used to promote angiogenesis as it aids in the formation of 
vascular sprouts. In order to hollow out a lumen within the construct to allow distribution 
of anti-cancer drugs similar to distribution of anti-cancer drugs in vivo, a combination of 
acidic and enzymatic degradation is employed. Non-cell coated and trypan blue stained 
fibers are exposed to acidic and enzymatic degradation conditions as a preliminary to cell 
coated fiber experiments and shows that the fiber does not degrade evenly. When cell 
coated fibers are exposed to acids and enzymes, swelling/bursting occurs which breaks the 
construct. Due to the inability to degrade chitosan fiber without destroying the cell 
construct as a result of present circumstance, an alternative method is proposed using 
chitosan electrospun mats to form tubes. Chitosan electrospun mats are manufactured by 
rolling the mat around a needle followed by neutralizing, washing, drying, and removal to 




viability as shown by live and Hoechst staining. Furthermore, when embedded in Matrigel, 
the tube is able to promote vascular sprouting and angiogenesis.  
The third aim of our study is to construct a vascularized liver cancer model using 
spheroids and cell coated tube. As such triculture spheroids and cell coated tube are 
embedded on Matrigel. Triculture spheroids, combining HepG2, fibroblasts, and 
endothelial cells, embedded on Matrigel result in vascular sprouts which can be used to 
help form a physical connection between the spheroid and the tube. Besides this, triculture 
spheroids on Matrigel can be used as an alternative to the aortic ring assay. Vascular sprouts 
emanating from the triculture spheroid can be used as a measure of how anti-cancer drugs 
affect angiogenesis. The anti-cancer drugs doxorubicin and sorafenib are both able to halt 
vascular sprouting growth and/or reverse it, similar to the aortic ring assay. 
Spheroids are either observed to anastomize, in which vascular sprouts from both the 
spheroids and tube interact with one another, or migrate, in which the spheroid migrates 
onto the tube. When fluorescent compounds FITC dextran and doxorubicin are injected 
into the system, the fluorescent compounds are shown in some of the vascular sprouts and 
within the spheroid region showing the presence of a nascent lumen. 
Overall, the model shows varying degrees of success as a drug cancer model by 
showing greater resistance similar to cancer in vivo. Aim 1 shows success as a model in 
that spheroids with different cell types and in collagen gel are able to resist the anti-cancer 
drug. Homopsheroids are able to resist drugs better than 2D cultures due to their geometry 
and gel system. Both homospheroids and heterospheroids are shown to promote drug 




For Aim 2, chitosan wetspun fibers require alternative methods to form a tissue 
engineered blood vessel with a lumen, however, at present chitosan electrospun tubes show 
success in being a platform for cells as well as containing a lumen. Chitosan film is shown 
to be chemically modified with EDC/NHS to heparin and adsorbed with fibronectin and 
able to adhere and proliferate cells. The chitosan wetspun fiber shows similar results. When 
the fiber is degraded to form a lumen, the fiber is shown to swell and ultimately, cause 
bursting of the cells coated on the construct. Unable to form a tissue engineered blood 
vessel using the chitosan wetspun fiber, an alternative chitosan electospun mat tube is used 
instead. Processed similarly to the chitosan wetspun fiber, electrospun tubes are able to 
adhere cells and form vascular sprouts on Matrigel. 
For Aim 3, spheroids and cell coated tube are combined together on Matrigel in 
order to form a vascularized liver model. Triculture spheroids exhibit vascular sprouts 
which after exposure to anti-cancer drugs, show retarded growth, similar to that of the 
aortic ring assay. Triculture spheroids on Matrigel with cell coated tubes, show 
anastomosis and migration. Anastomosis between the cells coating the tube and the 
spheroid is the desired outcome in order to form a vascularized liver model as it mimics 
angiogenesis in vivo in which blood vessels vascularize the tumor. Migration is an 
undesired event as it does not mimic angiogenesis and better models the phenomena of 
vascular co-option. Fluorescent compounds are injected into the model to illuminate the 
path by which these drugs travel through the model, as well as expose any open lumens. 
When fluorescent compounds FITC-dextran and doxorubicin are injected into the model, 
they show the presence of nascent lumen in the vascular sprouts and presence in the 




For future studies, further characterization studies can be employed on the 
vascularized cancer model to determine the mechanism by which combination therapy of 
sorafenib and doxorubicin is able to prolong overall survival in patients. Various theories 
exist as to why combination therapy works. The obvious theory is that combination therapy 
simply works because of the additive effects of multiple types of anti-cancer drugs. 
However, especially with anti-angiogenic drugs, the anti-angiogenic drugs may be able to 
restore the vasculature in what is known as vascular normalization.[150] As previously 
mentioned, blood vessels within cancer are leaky, as a result the concentration of anti-
cancer drugs inside the cancer decreases. One of the reasons for the leaky vessels is the 
overabundance of VEGF. Anti-angiogenic drugs affect VEGF and, thus, may result the 
restoration/normalization of the vessels such that anti-cancer drugs more readily enter into 
the tumor. To characterize this in the model, the model is exposed to sorafenib and the 
vasculature that exists between the spheroids and tube is monitored following the injection 
of doxorubicin. The intensity of the red fluorescence representing the doxorubicin 
concentration within the vasculature is then used to determine whether the sorafenib has 
caused vascular normalization.   
Overall, the vascularized liver model shows limited success. The vascularized 
model is able to form connections between the spheroid and the cell coated tube which 
could be used for the transport of anti-angiogenic drugs such as sorafenib into the spheroid, 
similar to what is expected in cancer when the drug is transported into the tumor. However, 
the advent of migration in the model confounds this expectation. Of course, each spheroid 
represents a single tumor and the varied fates demonstrated by each of the spheroid of 




the fate of tumors in the entire body. Although, this would make the model biomimetic, it 
would be troublesome to study the effects of the co-administration of doxorubicin and 
sorafenib as the model is not consistent throughout.  
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